<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "https://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" specific-use="sps-1.9" dtd-version="1.1" xml:lang="pt" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">abc</journal-id>
      <journal-title-group>
        <journal-title>Arquivos Brasileiros de Cardiologia</journal-title>
        <abbrev-journal-title abbrev-type="publisher">Arq. Bras. Cardiol.</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0066-782X</issn>
      <issn pub-type="epub">1678-4170</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Cardiologia - SBC</publisher-name>
        <publisher-loc>S&#227;o Paulo, SP, Brazil</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v3">GD6fMFfsM7QcYGXCzDGny8s</article-id>
      <article-id pub-id-type="other">00002</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v2">S0066-782X2010001600002</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v1">S0066-782X(10)09500602</article-id>
      <article-id pub-id-type="doi">10.1590/S0066-782X2010005000150</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Artigos Originais</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Avalia&#231;&#227;o angiogr&#225;fica do volume de placa e eventos cardiovasculares ap&#243;s implante de stents coronarianos</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Abreu-Silva</surname>
            <given-names>Erlon Oliveira de</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Quadros</surname>
            <given-names>Alexandre Schaan de</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Zanettini</surname>
            <given-names>Marco Tulio</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gottschall</surname>
            <given-names>Carlos Antonio</given-names>
          </name>
        </contrib>
      </contrib-group>
      <aff id="aff01">
        <addr-line>
          <named-content content-type="city">Porto Alegre</named-content>
          <named-content content-type="state">Rio Grande do Sul</named-content>
        </addr-line>
        <institution content-type="orgname">Funda&#231;&#227;o Universit&#225;ria de Cardiologia</institution>
        <institution content-type="orgdiv1">Instituto de Cardiologia do Rio Grande do Sul </institution>
        <country country="BR">Brazil</country>
      </aff>
      <pub-date date-type="collection" publication-format="electronic">
        <month>12</month>
        <year>2010</year>
      </pub-date>
      <volume>95</volume>
      <issue>6</issue>
      <fpage>679</fpage>
      <lpage>684</lpage>
      <history>
        <date date-type="rev-recd">
          <day>23</day>
          <month>06</month>
          <year>2010</year>
        </date>
        <date date-type="received">
          <day>13</day>
          <month>10</month>
          <year>2009</year>
        </date>
        <date date-type="accepted">
          <day>06</day>
          <month>07</month>
          <year>2010</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/" xml:lang="en">
          <license-p>This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>FUNDAMENTO: O volume de placa (VP) est&#225; relacionado a eventos cardiovasculares maiores (ECVM) ap&#243;s o implante de stents coronarianos. OBJETIVO: Avaliar a associa&#231;&#227;o entre o VP antes do procedimento avaliado por angiografia e desfechos cl&#237;nicos. M&#201;TODOS: Trata-se de estudo de coorte prospectivo incluindo pacientes submetidos a implante de stents coronarianos em um centro de refer&#234;ncia. O VP antes do implante do stent foi avaliado pela f&#243;rmula descrita por Giugliano (Am J Cardiol 2005; 95:173): VP = &#192; X (comprimento da les&#227;o) X [(di&#226;metro do vaso/2)&#178; - (di&#226;metro luminal m&#237;nimo/2)&#178;]. Os ECVM foram registrados no seguimento cl&#237;nico de um ano e an&#225;lise de regress&#227;o linear m&#250;ltipla foi realizada para identificar os preditores de eventos. RESULTADOS: A amostra estudada consistiu em 824 pacientes, com idade m&#233;dia de 60 &#177; 11 anos, sendo 70,0% do g&#234;nero masculino. O diabete melito estava presente em 21,0% e o comprometimento triarterial em 12,0%. O di&#226;metro m&#233;dio de refer&#234;ncia foi de 3,3 &#177; 3,2 mm, a m&#233;dia do comprimento da les&#227;o foi de 10,2 &#177; 4,7 mm e a m&#233;dia da estenose residual foi de 1,0% &#177; 12,0%. Os pacientes com ECVM apresentaram VP maior do que aqueles sem eventos (92,84 &#177; 42,85 vs 85 &#177; 46,85; p = 0,03). Outras vari&#225;veis associadas com ECVM na an&#225;lise univariada foram comprometimento triarterial, IAM, di&#226;metro do vaso e comprimento da les&#227;o tratada. O VP manteve a associa&#231;&#227;o significativa com ECVM ap&#243;s ajuste para as vari&#225;veis descritas e diabete melito. CONCLUS&#195;O: O volume da placa do ateroma antes do implante do stent foi maior nos pacientes que apresentaram ECVM no seguimento cl&#237;nico em um ano, independentemente de outros preditores de eventos.</p>
      </abstract>
      <kwd-group xml:lang="pt" kwd-group-type="author-generated">
        <kwd>Angioplastia transluminal percut&#226;nea coronariana</kwd>
        <kwd>doen&#231;a da art&#233;ria coronariana</kwd>
        <kwd>stents</kwd>
        <kwd>angiografia coronariana</kwd>
      </kwd-group>
      <pub-date publication-format="electronic" date-type="pub">
        <day>12</day>
        <month>11</month>
        <year>2010</year>
      </pub-date>
    </article-meta>
  </front>
  <body>
    <p>
      <bold>ARTIGO ORIGINAL</bold>
    </p>
    <p>
      <bold>Avalia&#231;&#227;o angiogr&#225;fica do volume de placa e eventos cardiovasculares ap&#243;s implante de <italic>stents</italic> coronarianos</bold>
    </p>
    <p>
      <bold>Erlon Oliveira de Abreu-Silva; Alexandre Schaan de Quadros; Marco Tulio Zanettini; Carlos Antonio Gottschall</bold>
    </p>
    <p>Instituto de Cardiologia do Rio Grande do Sul/Funda&#231;&#227;o Universit&#225;ria de Cardiologia, Porto Alegre, RS - Brasil</p>
    <p>
      <xref ref-type="corresp" rid="back">Correspond&#234;ncia</xref>
    </p>
    <p>
      <bold>RESUMO</bold>
    </p>
    <p><bold>FUNDAMENTO: </bold> O volume de placa (VP) est&#225; relacionado a eventos cardiovasculares maiores (ECVM) ap&#243;s o implante de <italic>stents</italic> coronarianos. </p>
    <p><bold>OBJETIVO:</bold> Avaliar a associa&#231;&#227;o entre o VP antes do procedimento avaliado por angiografia e desfechos cl&#237;nicos. </p>
    <p><bold>M&#201;TODOS:</bold> Trata-se de estudo de coorte prospectivo incluindo pacientes submetidos a implante de <italic>stents</italic> coronarianos em um centro de refer&#234;ncia. O VP antes do implante do <italic>stent</italic> foi avaliado pela f&#243;rmula descrita por Giugliano (Am J Cardiol 2005; 95:173): VP = &#192; X (comprimento da les&#227;o) X [(di&#226;metro do vaso/2)<sup>2</sup> - (di&#226;metro luminal m&#237;nimo/2)<sup>2</sup>]. Os ECVM foram registrados no seguimento cl&#237;nico de um ano e an&#225;lise de regress&#227;o linear m&#250;ltipla foi realizada para identificar os preditores de eventos. </p>
    <p><bold>RESULTADOS:</bold> A amostra estudada consistiu em 824 pacientes, com idade m&#233;dia de 60 &#177; 11 anos, sendo 70,0% do g&#234;nero masculino. O diabete melito estava presente em 21,0% e o comprometimento triarterial em 12,0%. O di&#226;metro m&#233;dio de refer&#234;ncia foi de 3,3 &#177; 3,2 mm, a m&#233;dia do comprimento da les&#227;o foi de 10,2 &#177; 4,7 mm e a m&#233;dia da estenose residual foi de 1,0% &#177; 12,0%. Os pacientes com ECVM apresentaram VP maior do que aqueles sem eventos (92,84 &#177; 42,85 <italic>vs</italic> 85 &#177; 46,85; p = 0,03). Outras vari&#225;veis associadas com ECVM na an&#225;lise univariada foram comprometimento triarterial, IAM, di&#226;metro do vaso e comprimento da les&#227;o tratada. O VP manteve a associa&#231;&#227;o significativa com ECVM ap&#243;s ajuste para as vari&#225;veis descritas e diabete melito. </p>
    <p><bold>CONCLUS&#195;O:</bold> O volume da placa do ateroma antes do implante do <italic>stent</italic> foi maior nos pacientes que apresentaram ECVM no seguimento cl&#237;nico em um ano, independentemente de outros preditores de eventos. </p>
    <p><bold>Palavras-chave: </bold> Angioplastia transluminal percut&#226;nea coronariana/progn&#243;stico, doen&#231;a da art&#233;ria coronariana, <italic>stents</italic>, angiografia coronariana.</p>
    <p>
      <bold>Introdu&#231;&#227;o</bold>
    </p>
    <p>As interven&#231;&#245;es coronarianas percut&#226;neas (ICP) s&#227;o o principal m&#233;todo de revasculariza&#231;&#227;o mioc&#225;rdica na pr&#225;tica cl&#237;nica atual<sup>1</sup>. Com o objetivo de estimar o risco e a evolu&#231;&#227;o cl&#237;nica desses pacientes, v&#225;rios modelos de predi&#231;&#227;o de risco e sucesso terap&#234;utico t&#234;m sido testados<sup>2-6</sup>. No entanto, a avalia&#231;&#227;o progn&#243;stica de tais pacientes &#233; limitada pela baixa acur&#225;cia preditiva dos modelos e escores de risco dispon&#237;veis atualmente<sup>3-6</sup>. Tal fato sugere a necessidade de identifica&#231;&#227;o de novas caracter&#237;sticas cl&#237;nicas e angiogr&#225;ficas, associadas a eventos cardiovasculares maiores (ECVM), no seguimento cl&#237;nico de longo prazo em pacientes submetidos a ICP.</p>
    <p>Estudos avaliando quantidade, &#225;rea, consist&#234;ncia e volume da placa ateroscler&#243;tica coronariana, tanto por cineangiocoronariografia quanto por ultrassonografia intravascular (IVUS), t&#234;m sido realizados<sup>7-13</sup> e mostram que o montante da placa, tanto pr&#233; quanto p&#243;s-ICP, pode desempenhar valor progn&#243;stico na evolu&#231;&#227;o da doen&#231;a e nos desfechos<sup>14-18</sup>. Embora a avalia&#231;&#227;o da placa ateroscler&#243;tica por IVUS seja um dos m&#233;todos com maior sensibilidade para sua avalia&#231;&#227;o, esta tecnologia tem custo elevado, n&#227;o est&#225; dispon&#237;vel em diversos centros e n&#227;o pode ser utilizada em les&#245;es subtotais sem pr&#233;-dilata&#231;&#227;o com bal&#227;o<sup>19-21</sup>.</p>
    <p>A avalia&#231;&#227;o do volume da placa por uma estimativa com base na angiografia foi recentemente descrita<sup>22</sup>. Entretanto, a influ&#234;ncia do volume da placa ateroscler&#243;tica avaliada por angiografia na evolu&#231;&#227;o cl&#237;nica de pacientes submetidos ao implante de <italic>stents</italic> coronarianos n&#227;o foi estudada e &#233; objetivo do presente estudo.</p>
    <p>
      <bold>M&#233;todos</bold>
    </p>
    <p>
      <bold>Pacientes</bold>
    </p>
    <p>Estudo de coorte prospectivo, no qual pacientes submetidos &#224; ICP com <italic>stents</italic> coronarianos, entre abr/1997 e dez/2001 em nossa institui&#231;&#227;o, foram considerados para inclus&#227;o. Foram exclu&#237;dos os pacientes com choque cardiog&#234;nico, implante de bal&#227;o intra-a&#243;rtico ou aqueles com estenose residual &gt; 30,0%, depois do implante do <italic>stent.</italic> As caracter&#237;sticas cl&#237;nicas, angiogr&#225;ficas, dados referentes aos procedimentos e complica&#231;&#245;es intra-hospitalares foram registrados prospectivamente em banco de dados <italic>Access</italic>.</p>
    <p>O estudo foi aprovado pelo conselho de &#233;tica institucional e os participantes assinaram o termo de consentimento.</p>
    <p>
      <bold>Caracter&#237;sticas cl&#237;nicas</bold>
    </p>
    <p>A hipertens&#227;o arterial sist&#234;mica foi considerada presente quando o paciente relatava hist&#243;ria pr&#233;via ou estava em uso de drogas anti-hipertensivas. O diabete melito e a dislipidemia foram definidos como hist&#243;ria pr&#233;via ou uso de hipoglicemiantes orais ou insulina, ou estatina, respectivamente. Hist&#243;ria familiar foi definida pela ocorr&#234;ncia de IAM ou morte s&#250;bita paterna (&lt; 45 anos) ou materna (&lt; 55 anos). Angina est&#225;vel foi definida como a estabilidade do padr&#227;o de desencadeamento da dor nos &#250;ltimos dois meses antes do procedimento. Angina inst&#225;vel foi definida como a piora da intensidade e/ou frequ&#234;ncia do padr&#227;o de angina nos &#250;ltimos dois meses antes do procedimento, com ou sem dor tor&#225;cica em repouso. Infarto agudo do mioc&#225;rdio (IAM) como indica&#231;&#227;o para o implante de <italic>stent</italic> foi definido como dor tor&#225;cica e supradesnivelamento do segmento ST que necessitaram revasculariza&#231;&#227;o imediata da art&#233;ria relacionada ao infarto.</p>
    <p>
      <bold>Procedimento de implante de <italic>stent</italic> coronariano</bold>
    </p>
    <p>Os pacientes estavam recebendo aspirina e tienopirid&#237;nicos por ocasi&#227;o da ICP. Foram administrados <italic>bolus</italic> intravenosos de heparina n&#227;o fracionada para atingir um TCA &gt; 300 segundos, e nitroglicerina intracoronariana foi administrada previamente &#224; angiografia. Os procedimentos de implante de <italic>stents</italic> foram realizados conforme descrito na literatura<sup>23</sup>; sendo que <italic>stents</italic> convencionais foram implantados em todos os casos.</p>
    <p>Sucesso cl&#237;nico dos procedimentos foi definido como fluxo coronariano TIMI 3 e estenose residual &lt; 30,0% ap&#243;s implanta&#231;&#227;o do <italic>stent</italic>, sem ocorr&#234;ncia de morte, infarto agudo do mioc&#225;rdio ou cirurgia de revasculariza&#231;&#227;o mioc&#225;rdica de emerg&#234;ncia. Infarto agudo do mioc&#225;rdio foi definido como eleva&#231;&#227;o da creatinaquinase fra&#231;&#227;o MB (CK-MB) &gt; 3 vezes o limite superior da normalidade ou o desenvolvimento de novas ondas Q patol&#243;gicas no eletrocardiograma.</p>
    <p>
      <bold>An&#225;lise angiogr&#225;fica</bold>
    </p>
    <p>Todas as an&#225;lises angiogr&#225;ficas foram executadas com angiografia quantitativa (<italic>Siemens Axiom Artis,</italic> Munique, Alemanha). O di&#226;metro do vaso-alvo foi definido como o di&#226;metro m&#233;dio dos segmentos proximal e distal &#224; les&#227;o. A gravidade da estenose foi medida em duas proje&#231;&#245;es ortogonais. Les&#245;es mais longas foram consideradas como uma &#250;nica les&#227;o somente quando um segmento normal &lt; 10 mm de comprimento se encontrava entre elas. As estenoses foram classificadas de acordo com crit&#233;rios estabelecidos pelo <italic>American College of Cardiology (ACC)</italic><sup>24</sup>; sendo que les&#245;es complexas foram definidas como aquelas do tipo B2/C.</p>
    <p>O volume da placa ateroscler&#243;tica foi calculado pela f&#243;rmula proposta por Giugliano e cols.<sup>22</sup>: VP = &#960; X (Comprimento da Les&#227;o) X [(DRV/2)<sup>2</sup> - (DLM/2)<sup>2</sup>]. Considerou-se &#960; = 3,14; DRV = di&#226;metro de refer&#234;ncia do vaso em mm; DLM = di&#226;metro luminal m&#237;nimo em mm.</p>
    <p>
      <bold>Seguimento e desfechos cl&#237;nicos</bold>
    </p>
    <p>Os pacientes foram acompanhados durante um ano por avalia&#231;&#227;o cl&#237;nica em consult&#243;rio, contato com o m&#233;dico respons&#225;vel ou entrevista por telefone. O controle angiogr&#225;fico foi realizado na suspeita de isquemia mioc&#225;rdica recorrente.</p>
    <p>O desfecho prim&#225;rio do estudo foi uma combina&#231;&#227;o de ECAM incluindo morte relacionada a causas card&#237;acas, infarto agudo do mioc&#225;rdio (IAM), cirurgia de revasculariza&#231;&#227;o do mioc&#225;rdio (CRM) e revasculariza&#231;&#227;o percut&#226;nea do vaso-alvo (RVA) at&#233; um ano ap&#243;s o procedimento inicial de implante do <italic>stent</italic>.</p>
    <p>
      <bold>An&#225;lise estat&#237;stica</bold>
    </p>
    <p>As vari&#225;veis categ&#243;ricas foram expressas em percentis e as vari&#225;veis cont&#237;nuas conforme sua m&#233;dia &#177; desvio-padr&#227;o (DP). As diferen&#231;as entre os dois grupos estudados foram avaliadas pelo qui-quadrado (vari&#225;veis categ&#243;ricas) e pelo teste t (vari&#225;veis cont&#237;nuas). A sobrevida livre de ECAM durante o per&#237;odo de acompanhamento de um ano foi analisada e a diferen&#231;a entre as curvas de sobrevida foi avaliada pelo m&#233;todo de <italic>log-rank</italic>.</p>
    <p>An&#225;lise multivariada por regress&#227;o linear m&#250;ltipla foi realizada para identificar os preditores de ECAM em um ano. As vari&#225;veis inclu&#237;das no modelo foram associadas com ECAM na an&#225;lise univariada (volume da placa, extens&#227;o da les&#227;o, di&#226;metro de refer&#234;ncia, IAM e comprometimento triarterial) ou com signific&#226;ncia biol&#243;gica demonstrada em estudos pr&#233;vios (diabete melito, extens&#227;o da les&#227;o, di&#226;metro de refer&#234;ncia, IAM e comprometimento triarterial).</p>
    <p>Para todos os testes realizados, foram consideradas estatisticamente significativas as associa&#231;&#245;es com p &lt; 0,05.</p>
    <p>
      <bold>Resultados</bold>
    </p>
    <p>Neste estudo, 824 pacientes submetidos ao implante de 891 <italic>stents</italic> preencheram os crit&#233;rios de inclus&#227;o e tiveram o seguimento de um ano p&#243;s-ICP.</p>
    <p>As caracter&#237;sticas cl&#237;nicas est&#227;o apresentadas na <xref ref-type="table" rid="t1">Tabela 1</xref>, observando-se que os indiv&#237;duos eram predominantemente homens de meia idade e que apresentavam quadro de angina inst&#225;vel. A apresenta&#231;&#227;o cl&#237;nica de IAM foi mais frequente no grupo de pacientes que apresentou ECAM, sem signific&#226;ncia estat&#237;stica na compara&#231;&#227;o entre as outras vari&#225;veis analisadas.</p>
    <table-wrap id="t1">
      <graphic xlink:href="1678-4170-abc-95-06-0679-00150-gt01.jpg"/></table-wrap>
    <p>A avalia&#231;&#227;o angiogr&#225;fica demonstrou que o di&#226;metro m&#233;dio do vaso estudado foi de 3,3 &#177; 0,32 mm, a extens&#227;o m&#233;dia da les&#227;o que sofreu interven&#231;&#227;o era de 10,2 &#177; 4,7 mm, e o percentual da estenose residual p&#243;s-<italic>stent</italic> foi de 1 &#177; 12,0% (<xref ref-type="table" rid="t2">Tabela 2</xref>). Os pacientes que apresentaram ECAM apresentavam mais frequentemente comprometimento triarterial, vasos mais finos e les&#245;es mais longas.</p>
    <table-wrap id="t2">
      <graphic xlink:href="1678-4170-abc-95-06-0679-00150-gt02.jpg"/></table-wrap>
    <p>O volume da placa ateroscler&#243;tica antes do procedimento foi significativamente maior nos indiv&#237;duos que, um ano ap&#243;s a interven&#231;&#227;o percut&#226;nea, apresentaram o desfecho composto de ECAM em compara&#231;&#227;o &#224;queles sem eventos (93 &#177; 43 mm<sup>3</sup> x 85 &#177; 46 mm<sup>3</sup>; p = 0,03). Tal resultado ocorreu independentemente das demais vari&#225;veis analisadas no modelo de an&#225;lise multivariada (di&#226;metro de refer&#234;ncia, extens&#227;o da les&#227;o, comprometimento triarterial, diabete melito e IAM) (<xref ref-type="table" rid="t3">Tabela 3</xref> e <xref ref-type="fig" rid="f1">Figura 1</xref>).</p>
    <table-wrap id="t3">
      <graphic xlink:href="1678-4170-abc-95-06-0679-00150-gt03.jpg"/></table-wrap>
    <fig id="f1">
      <graphic xlink:href="1678-4170-abc-95-06-0679-00150-gf01.jpg"/></fig>
    <p>
      <bold>Discuss&#227;o</bold>
    </p>
    <p>Nossos resultados demonstram que os indiv&#237;duos que apresentaram eventos cardiovasculares maiores (ECAM), no per&#237;odo de um ano ap&#243;s implante de <italic>stent,</italic> tinham volume de placa antes do procedimento significativamente maior do que aqueles indiv&#237;duos que n&#227;o apresentaram eventos no mesmo per&#237;odo. Esse resultado se manteve independentemente de outros preditores de eventos ap&#243;s a realiza&#231;&#227;o de ICP, conforme demonstrado pela an&#225;lise multivariada realizada.</p>
    <p>O ultrassom intracoronariano &#233; um m&#233;todo mais acurado do que a angiografia para avalia&#231;&#227;o do volume de placa ateroscler&#243;tica<sup>13,19</sup>; mas n&#227;o est&#225; dispon&#237;vel em todos os centros e agrega custos aos procedimentos. Al&#233;m disso, em estenoses subtotais n&#227;o &#233; poss&#237;vel a introdu&#231;&#227;o do cateter de ultrassom sem pr&#233;via dilata&#231;&#227;o com bal&#227;o, o que inviabiliza a avalia&#231;&#227;o acurada das estenoses mais severas. Para testar a hip&#243;tese da associa&#231;&#227;o entre o volume da placa pr&#233;-procedimento e eventos no seguimento, a exclus&#227;o das estenoses mais severas representaria um vi&#233;s significativo, j&#225; que estes seriam os casos nos quais uma maior incid&#234;ncia de eventos seria esperada.</p>
    <p>A avalia&#231;&#227;o da placa ateroscler&#243;tica por angiografia utilizada no presente estudo foi descrita por Giuliano e cols.<sup>22</sup> e n&#227;o apresenta as limita&#231;&#245;es descritas acima. A f&#243;rmula matem&#225;tica proposta estima o volume da placa com base no di&#226;metro de refer&#234;ncia, di&#226;metro luminal m&#237;nimo e extens&#227;o da les&#227;o. Em nosso estudo, o volume de placa avaliado pela angiografia apresentou valor preditivo independente para eventos cardiovasculares, sendo que o risco ajustado por an&#225;lise multivariada foi de 1,04 (IC = 1,02 - 1,07).</p>
    <p>Embora um risco adicional de 4,0% possa ser considerado lim&#237;trofe, &#233; importante considerar que a vari&#225;vel "volume da placa" foi expressa em mil&#237;metros c&#250;bicos, variando entre 93 &#177; 43 mm<sup>3</sup> e 85 &#177; 46 mm<sup>3</sup> em cada grupo. Portanto, o aumento de 4,0% de risco refere-se a cada mil&#237;metro c&#250;bico de placa, que &#233; muito inferior ao desvio-padr&#227;o de cada grupo. Se tal vari&#225;vel tivesse sido utilizada conforme incrementos de 10 mm<sup>3</sup>; por exemplo, ter&#237;amos um aumento de 40,0% no risco.</p>
    <p>Nessa tend&#234;ncia, Prati e cols.<sup>18</sup> descreveram a rela&#231;&#227;o direta e significativa entre o montante da placa - avaliado por angiografia - e o volume da mesma avaliada por IVUS com a intensidade de prolifera&#231;&#227;o neointimal. Achados semelhantes, correlacionando o percentual de &#225;rea da placa residual e reestenose, foram descritos nos estudos OARS<sup>25</sup>; ABACAS<sup>26</sup> e GUIDE II<sup>27</sup>. Berry e cols.<sup>13</sup>; comparando achados angiogr&#225;ficos e ultrassonogr&#225;ficos de 525 indiv&#237;duos, mostraram correla&#231;&#227;o significativa na mensura&#231;&#227;o do volume da placa pelos dois m&#233;todos. No mesmo trabalho, demonstrou-se que os indiv&#237;duos com evolu&#231;&#227;o angiogr&#225;fica da doen&#231;a tinham maiores medidas volum&#233;tricas de placa por IVUS.</p>
    <p>Em nosso estudo, n&#227;o foram explorados os mecanismos respons&#225;veis pela associa&#231;&#227;o entre o volume da placa ateroscler&#243;tica pr&#233;-procedimento e a incid&#234;ncia de eventos cl&#237;nicos. Uma poss&#237;vel explica&#231;&#227;o poderia estar relacionada a um maior conte&#250;do de ateroma e c&#233;lulas inflamat&#243;rias nas art&#233;rias com ateromas mais volumosos. A reestenose e a necessidade de novas revasculariza&#231;&#245;es do vaso-alvo s&#227;o os principais eventos ap&#243;s as ICP, e a associa&#231;&#227;o entre a prolifera&#231;&#227;o neointimal e os fen&#244;menos inflamat&#243;rios &#233; bem conhecida<sup>28,29</sup>.</p>
    <p>As implica&#231;&#245;es cl&#237;nicas da associa&#231;&#227;o entre o volume de placa pr&#233;-procedimento e o risco de eventos cardiovasculares em pacientes submetidos a ICPs com <italic>stents</italic> referem-se &#224; estratifica&#231;&#227;o de risco a longo prazo nesse cen&#225;rio cl&#237;nico, conforme abordado por in&#250;meros estudos pr&#233;vios<sup>2-6,27,30-33</sup>. Na maioria dos estudos, os preditores estabelecidos de novos eventos foram diabete melito, di&#226;metro de refer&#234;ncia do vaso tratado e extens&#227;o da les&#227;o.</p>
    <p>Nosso grupo desenvolveu e validou um escore de pontos para avalia&#231;&#227;o de eventos, no qual foi poss&#237;vel identificar subgrupos de alto e baixo risco para novas revasculariza&#231;&#245;es do vaso-alvo<sup>6</sup>. A avalia&#231;&#227;o angiogr&#225;fica do volume de placa poderia ser uma nova vari&#225;vel a ser inclu&#237;da em algoritmos de estratifica&#231;&#227;o de risco, considerando que a acur&#225;cia diagn&#243;stica de tais modelos &#233; relativamente limitada.</p>
    <p>Outro aspecto importante &#233; se o volume de placa tamb&#233;m seria preditivo de eventos em pacientes submetidos ao implante de <italic>stents</italic> farmacol&#243;gicos, que t&#234;m sido usados com frequ&#234;ncia cada vez maior nos &#250;ltimos anos. A capacidade desses novos dispositivos em diminuir a hiperplasia intimal, que ocorre ap&#243;s o dano vascular imposto pelo <italic>stent</italic> ou bal&#227;o, proporcionou uma diminui&#231;&#227;o significativa das taxas de reestenose e de revasculariza&#231;&#245;es do vaso-alvo<sup>34,35</sup>; sendo que os preditores de eventos em pacientes tratados com <italic>stents</italic> farmacol&#243;gicos s&#227;o semelhantes &#224;queles que receberam <italic>stents</italic> convencionais<sup>36-38</sup>. No entanto, para demonstrar um valor preditivo adicional do volume de placa aos preditores j&#225; conhecidos em pacientes tratados com <italic>stents</italic> farmacol&#243;gicos, seria necess&#225;rio um n&#250;mero de pacientes muito maior do que o do presente estudo, j&#225; que a incid&#234;ncia de eventos com os <italic>stents</italic> farmacol&#243;gicos &#233; muito menor.</p>
    <p>Em conclus&#227;o, demonstramos que o volume da placa ateroscler&#243;tica avaliado antes do implante de <italic>stent</italic> por um m&#233;todo angiogr&#225;fico associou-se com eventos cardiovasculares a longo prazo. Tais resultados poder&#227;o ser utilizados para avalia&#231;&#245;es subsequentes, objetivando investigar se o volume de placa pode aumentar a acur&#225;cia diagn&#243;stica de algoritmos de estratifica&#231;&#227;o de risco j&#225; estabelecidos, e se esta associa&#231;&#227;o tamb&#233;m ocorre em pacientes tratados com <italic>stents</italic> farmacol&#243;gicos.</p>
    <p>Limita&#231;&#245;es inerentes ao delineamento do estudo devem ser consideradas e incluem falta de randomiza&#231;&#227;o, cegamento e seguimento a longo prazo. Ensaios cl&#237;nicos randomizados comparando essa t&#233;cnica de avalia&#231;&#227;o da placa ateroscler&#243;tica coronariana &#224;s convencionais atualmente dispon&#237;veis tornam-se essenciais para a consolida&#231;&#227;o e valida&#231;&#227;o deste m&#233;todo diagn&#243;stico e progn&#243;stico da doen&#231;a arterial coronariana.</p>
    <p>
      <bold>Potencial Conflito de Interesses</bold>
    </p>
    <p>Declaro n&#227;o haver conflito de interesses pertinentes.</p>
    <p>
      <bold>Fontes de Financiamento</bold>
    </p>
    <p>O presente estudo n&#227;o teve fontes de financiamento externas.</p>
    <p>
      <bold>Vincula&#231;&#227;o Acad&#234;mica</bold>
    </p>
    <p>N&#227;o h&#225; vincula&#231;&#227;o deste estudo a programas de p&#243;s-gradua&#231;&#227;o.</p>
    <p>
      <fn id="back" fn-type="corresp">
        <p>Correspond&#234;ncia:</p>
        <p> Alexandre Schaan de Quadros </p>
        <p> Av. Princesa Isabel, 370 - Santana </p>
        <p> 90620-000 - Porto Alegre, RS - Brasil </p>
        <p> E-mail: </p>
        <p><email xlink:href="editoracao-pc@cardiologia.org.br">editoracao-pc@cardiologia.org.br</email>, </p>
        <p>
          <email xlink:href="alesq@terra.com.br">alesq@terra.com.br</email>
        </p>
      </fn>
    </p>
    <p>Artigo recebido em 13/10/09; revisado recebido em 23/06/10; aceito em 06/07/10.</p>
  </body>
  <back>
    <ref-list>
      <ref id="B1">
        <mixed-citation>1. Lloyd-Jones    D, Adams R, Carnethon M, De Simone G, Ferguson TB, Flegal K, et al. Heart disease    and Stroke Statistic-2009 update: a report from the American Heart Association    Statistics Committee and Stroke Statistics Subcomittee. Circulation. 2009; 119    (3): e21-e181.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Heart disease and Stroke Statistic-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcomittee</article-title>
          <source>Circulation</source>
          <date>
            <year>2009</year>
          </date>
          <fpage>e21</fpage>
          <lpage>e181</lpage>
          <issue>3</issue>
          <volume>119</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Lloyd-Jones</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Adams</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Carnethon</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>De Simone</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Ferguson</surname>
              <given-names>TB</given-names>
            </name>
            <name>
              <surname>Flegal</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B2">
        <mixed-citation>2. Gottschall CA,    Miler VV, Yordi LM, Cardoso CR, Rodrigues LC. Detection of restenosis after    percutaneous transluminal coronary angioplasty by an angiographic score. J Invasive    Cardiol. 1998; 10 (1): 1-11.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Detection of restenosis after percutaneous transluminal coronary angioplasty by an angiographic score</article-title>
          <source>J Invasive Cardiol</source>
          <date>
            <year>1998</year>
          </date>
          <fpage>1</fpage>
          <lpage>11</lpage>
          <issue>1</issue>
          <volume>10</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Gottschall</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Miler</surname>
              <given-names>VV</given-names>
            </name>
            <name>
              <surname>Yordi</surname>
              <given-names>LM</given-names>
            </name>
            <name>
              <surname>Cardoso</surname>
              <given-names>CR</given-names>
            </name>
            <name>
              <surname>Rodrigues</surname>
              <given-names>LC</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B3">
        <mixed-citation>3. de Feyter PJ,    Kay P, Disco C, Serruys PW. Reference chart derived from post-stent-implantation    intravascular ultrasound predictors of 6-month expected restenosis on quantitative    coronary angiography. Circulation. 1999; 100 (17): 1777-83.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Reference chart derived from post-stent-implantation intravascular ultrasound predictors of 6-month expected restenosis on quantitative coronary angiography</article-title>
          <source>Circulation</source>
          <date>
            <year>1999</year>
          </date>
          <fpage>1777</fpage>
          <lpage>83</lpage>
          <issue>17</issue>
          <volume>100</volume>
          <person-group person-group-type="author">
            <name>
              <surname>de Feyter</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Kay</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Disco</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Serruys</surname>
              <given-names>PW</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B4">
        <mixed-citation>4. Ellis SG, Bajzer    CT, Bhatt DL. Real-world bare metal stenting: identification of patients at    low or very low risk of 9-month coronary revascularization. Catheter Cardiovasc    Interv. 2004; 63 (2): 135-40.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Real-world bare metal stenting: identification of patients at low or very low risk of 9-month coronary revascularization</article-title>
          <source>Catheter Cardiovasc Interv</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>135</fpage>
          <lpage>40</lpage>
          <issue>2</issue>
          <volume>63</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Ellis</surname>
              <given-names>SG</given-names>
            </name>
            <name>
              <surname>Bajzer</surname>
              <given-names>CT</given-names>
            </name>
            <name>
              <surname>Bhatt</surname>
              <given-names>DL</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B5">
        <mixed-citation>5. Singh M, Gersh    BJ, McClelland RL. Clinical and angiographic predictors of restenosis after    percutaneous coronary intervention: insights from the prevention of restenosis    with tranilast and its outcomes (PRESTO) trial. Circulation. 2004; 109 (22):    2727-31.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Clinical and angiographic predictors of restenosis after percutaneous coronary intervention: insights from the prevention of restenosis with tranilast and its outcomes (PRESTO) trial</article-title>
          <source>Circulation</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>2727</fpage>
          <lpage>31</lpage>
          <issue>22</issue>
          <volume>109</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Singh</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Gersh</surname>
              <given-names>BJ</given-names>
            </name>
            <name>
              <surname>McClelland</surname>
              <given-names>RL</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B6">
        <mixed-citation>6. Quadros AS,    Diemer F, Welter D, Modkovski T, Sarmento-Leite R, Gottschall CA. Validation    of a risk score for target vessel revascularization after coronary stent implantation.    J Invasive Cardiol. 2009; 21 (12): 618-22.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Validation of a risk score for target vessel revascularization after coronary stent implantation</article-title>
          <source>J Invasive Cardiol</source>
          <date>
            <year>2009</year>
          </date>
          <fpage>618</fpage>
          <lpage>22</lpage>
          <issue>12</issue>
          <volume>21</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Quadros</surname>
              <given-names>AS</given-names>
            </name>
            <name>
              <surname>Diemer</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Welter</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Modkovski</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Sarmento-Leite</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Gottschall</surname>
              <given-names>CA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B7">
        <mixed-citation>7. Frimerman A,    Miller HI, Siegel RJ, Rosenschein U, Roth A, Keren G. Intravascular ultrasound    imaging of myocardial-infarction-related arteries after percutaneous transluminal    coronary angioplasty reveals significant plaque burden and compensatory enlargement.    Int J Cardiovasc Intervent. 1999; 2 (2): 101-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Intravascular ultrasound imaging of myocardial-infarction-related arteries after percutaneous transluminal coronary angioplasty reveals significant plaque burden and compensatory enlargement</article-title>
          <source>Int J Cardiovasc Intervent</source>
          <date>
            <year>1999</year>
          </date>
          <fpage>101</fpage>
          <lpage>7</lpage>
          <issue>2</issue>
          <volume>2</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Frimerman</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Miller</surname>
              <given-names>HI</given-names>
            </name>
            <name>
              <surname>Siegel</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Rosenschein</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Roth</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Keren</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B8">
        <mixed-citation>8. Hartmann M,    von Birgelen C, Mintz GS, Verhorst PM, Erbel R. Relation between baseline plaque    burden and subsequent remodeling of atherosclerotic left main coronary arteries:    a serial intravascular ultrasound study with long-term (&gt; or =12 months)    follow-up. Eur Heart J. 2006; 27 (15): 1778-84.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Relation between baseline plaque burden and subsequent remodeling of atherosclerotic left main coronary arteries: a serial intravascular ultrasound study with long-term (&gt; or =12 months) follow-up</article-title>
          <source>Eur Heart J</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>1778</fpage>
          <lpage>84</lpage>
          <issue>15</issue>
          <volume>27</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Hartmann</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>von Birgelen</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Mintz</surname>
              <given-names>GS</given-names>
            </name>
            <name>
              <surname>Verhorst</surname>
              <given-names>PM</given-names>
            </name>
            <name>
              <surname>Erbel</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B9">
        <mixed-citation>9. Wong CB, Porter    TR, Xie F, Deligonul U. Segmental analysis of coronary arteries with equivalent    plaque burden by intravascular ultrasound in patients with and without angiographically    significant coronary artery disease. Am J Cardiol. 1995 15; 76 (8): 598-601.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Segmental analysis of coronary arteries with equivalent plaque burden by intravascular ultrasound in patients with and without angiographically significant coronary artery disease</article-title>
          <source>Am J Cardiol.</source>
          <date>
            <year>1995</year>
          </date>
          <fpage>598</fpage>
          <lpage>601</lpage>
          <issue>8</issue>
          <volume>15</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Wong</surname>
              <given-names>CB</given-names>
            </name>
            <name>
              <surname>Porter</surname>
              <given-names>TR</given-names>
            </name>
            <name>
              <surname>Xie</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Deligonul</surname>
              <given-names>U</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B10">
        <mixed-citation>10. Honda Y, Yock    PG, Fitzgerald PJ. Impact of residual plaque burden on clinical outcomes of    coronary interventions. Catheter Cardiovasc Interv. 1999; 46 (3): 265-76.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Impact of residual plaque burden on clinical outcomes of coronary interventions</article-title>
          <source>Catheter Cardiovasc Interv</source>
          <date>
            <year>1999</year>
          </date>
          <fpage>265</fpage>
          <lpage>76</lpage>
          <issue>3</issue>
          <volume>46</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Honda</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Yock</surname>
              <given-names>PG</given-names>
            </name>
            <name>
              <surname>Fitzgerald</surname>
              <given-names>PJ</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B11">
        <mixed-citation>11. Sahara M, Kirigaya    H, Oikawa Y, Yajima J, Nagashima K, Hara H, et al. Soft plaque detected on intravascular    ultrasound is the strongest predictor of in-stent restenosis: an intravascular    ultrasound study. Eur Heart J. 2004; 25 (22): 2026-33.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Soft plaque detected on intravascular ultrasound is the strongest predictor of in-stent restenosis: an intravascular ultrasound study</article-title>
          <source>Eur Heart J</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>2026</fpage>
          <lpage>33</lpage>
          <issue>22</issue>
          <volume>25</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Sahara</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kirigaya</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Oikawa</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Yajima</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Nagashima</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Hara</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B12">
        <mixed-citation>12. Sabate M, Marijnissen    JP, Carlier SG, Kay IP, van der Giessen WJ, Coen VL, et al. Residual plaque    burden, delivered dose, and tissue composition predict 6-month outcome after    balloon angioplasty and beta-radiation therapy. Circulation. 2000 30; 101 (21):    2472-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Residual plaque burden, delivered dose, and tissue composition predict 6-month outcome after balloon angioplasty and beta-radiation therapy</article-title>
          <source>Circulation</source>
          <date>
            <year>2000</year>
          </date>
          <fpage>2472</fpage>
          <lpage>7</lpage>
          <issue>21</issue>
          <volume>30</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Sabate</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Marijnissen</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Carlier</surname>
              <given-names>SG</given-names>
            </name>
            <name>
              <surname>Kay</surname>
              <given-names>IP</given-names>
            </name>
            <name>
              <surname>van der Giessen</surname>
              <given-names>WJ</given-names>
            </name>
            <name>
              <surname>Coen</surname>
              <given-names>VL</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B13">
        <mixed-citation>13. Berry C, L'Allier    PL, Gr&#233;goire J, Lesp&#233;rance J, Levesque S, Ibrahim R, et al. Comparison    of intravascular ultrasound and quantitative coronary angiography for the assessment    of coronary artery disease progression. Circulation. 2007; 115 (14): 1851-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Comparison of intravascular ultrasound and quantitative coronary angiography for the assessment of coronary artery disease progression</article-title>
          <source>Circulation</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>1851</fpage>
          <lpage>7</lpage>
          <issue>14</issue>
          <volume>115</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Berry</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>L'Allier</surname>
              <given-names>PL</given-names>
            </name>
            <name>
              <surname>Gr&#233;goire</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Lesp&#233;rance</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Levesque</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ibrahim</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B14">
        <mixed-citation>14. Hong MK, Park    SW, Lee CW, Kim YH, Song JM, Kang DH, et al. Relation between residual plaque    burden after stenting and six-month angiographic restenosis. Am J Cardiol. 2002;    89 (4): 368-71.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Relation between residual plaque burden after stenting and six-month angiographic restenosis</article-title>
          <source>Am J Cardiol</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>368</fpage>
          <lpage>71</lpage>
          <issue>4</issue>
          <volume>89</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Hong</surname>
              <given-names>MK</given-names>
            </name>
            <name>
              <surname>Park</surname>
              <given-names>SW</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>CW</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>YH</given-names>
            </name>
            <name>
              <surname>Song</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Kang</surname>
              <given-names>DH</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B15">
        <mixed-citation>15. Shiran A, Weissman    NJ, Leiboff B, Kent KM, Pichard A, Satler LF, et al. Effect of preintervention    plaque burden on subsequent intimal hyperplasia in stented coronary artery lesions.    Am J Cardiol. 2000; 86 (12): 1318-21.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Effect of preintervention plaque burden on subsequent intimal hyperplasia in stented coronary artery lesions</article-title>
          <source>Am J Cardiol</source>
          <date>
            <year>2000</year>
          </date>
          <fpage>1318</fpage>
          <lpage>21</lpage>
          <issue>12</issue>
          <volume>86</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Shiran</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Weissman</surname>
              <given-names>NJ</given-names>
            </name>
            <name>
              <surname>Leiboff</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Kent</surname>
              <given-names>KM</given-names>
            </name>
            <name>
              <surname>Pichard</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Satler</surname>
              <given-names>LF</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B16">
        <mixed-citation>16. Alfonso F,    Garc&#237;a P, Pimentel G, Hern&#225;ndez R, Sabat&#233; M, Escaned J,    et al. Intravascular ultrasound study. Predictors and implications of residual    plaque burden after coronary stenting: an intravascular ultrasound study. Am    Heart J. 2003; 145 (2): 254-61.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Intravascular ultrasound study: Predictors and implications of residual plaque burden after coronary stenting: an intravascular ultrasound study</article-title>
          <source>Am Heart J</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>254</fpage>
          <lpage>61</lpage>
          <issue>2</issue>
          <volume>145</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Alfonso</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Garc&#237;a</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Pimentel</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Hern&#225;ndez</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Sabat&#233;</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Escaned</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B17">
        <mixed-citation>17. Hong YJ, Mintz    GS, Kim SW, Okabe T, Lu L, Bui AB, et al. Peri-stent reference segment plaque    burden is associated with disease progression in saphenous vein grafts (a serial    intravascular ultrasound assessment). Am J Cardiol. 2007; 100 (8): 1233-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Peri-stent reference segment plaque burden is associated with disease progression in saphenous vein grafts (a serial intravascular ultrasound assessment)</article-title>
          <source>Am J Cardiol</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>1233</fpage>
          <lpage>8</lpage>
          <issue>8</issue>
          <volume>100</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Hong</surname>
              <given-names>YJ</given-names>
            </name>
            <name>
              <surname>Mintz</surname>
              <given-names>GS</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>SW</given-names>
            </name>
            <name>
              <surname>Okabe</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Lu</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Bui</surname>
              <given-names>AB</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B18">
        <mixed-citation>18. Prati F, Di    Mario C, Moussa I, Reimers B, Mallus MT, Parma A, et al. In-stent neointimal    proliferation correlates with the amount of residual plaque burden outside the    stent: an intravascular ultrasound study. Circulation. 1999; 99 (8): 1011-4.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>In-stent neointimal proliferation correlates with the amount of residual plaque burden outside the stent: an intravascular ultrasound study</article-title>
          <source>Circulation</source>
          <date>
            <year>1999</year>
          </date>
          <fpage>1011</fpage>
          <lpage>4</lpage>
          <issue>8</issue>
          <volume>99</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Prati</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Di Mario</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Moussa</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Reimers</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Mallus</surname>
              <given-names>MT</given-names>
            </name>
            <name>
              <surname>Parma</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B19">
        <mixed-citation>19. Schoenhagen    P, Nissen SE. Assessing coronary plaque burden and plaque vulnerability: atherosclerosis    imaging with IVUS and emerging noninvasive modalities. Am Heart Hosp J. 2003;    2 (2): 164-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Assessing coronary plaque burden and plaque vulnerability: atherosclerosis imaging with IVUS and emerging noninvasive modalities</article-title>
          <source>Am Heart Hosp J</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>164</fpage>
          <lpage>9</lpage>
          <issue>2</issue>
          <volume>2</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Schoenhagen</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Nissen</surname>
              <given-names>SE</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B20">
        <mixed-citation>20. Tuzcu EM, Schoenhagen    P. Atherosclerosis imaging: intravascular ultrasound. 2004; 64 (l2): 1-7.</mixed-citation>
        <element-citation publication-type="journal">
          <source>Atherosclerosis imaging: intravascular ultrasound</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>1</fpage>
          <lpage>7</lpage>
          <issue>l2</issue>
          <volume>64</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Tuzcu</surname>
              <given-names>EM</given-names>
            </name>
            <name>
              <surname>Schoenhagen</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B21">
        <mixed-citation>21. Nissen S. Coronary    angiography and intravascular ultrasound. Am J Cardiol. 2001; 87 (4A): 15A-20A.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Coronary angiography and intravascular ultrasound</article-title>
          <source>Am J Cardiol</source>
          <date>
            <year>2001</year>
          </date>
          <fpage>15A</fpage>
          <lpage>20A</lpage>
          <issue>4A</issue>
          <volume>87</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Nissen</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B22">
        <mixed-citation>22. Giugliano GR,    Kuntz RE, Popma JJ, Cutlip DE, Baim DS, on behalf of the Saphenous Vein Graft    Angioplasty Free of Emboli Randomized (SAFER) Trial Investigators. Determinants    of 30-day adverse events following saphenous vein graft intervention with and    without a distal occlusion embolic protection device. Am J Cardiol. 2005; 95    (2): 173-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>on behalf of the Saphenous Vein Graft Angioplasty Free of Emboli Randomized (SAFER) Trial Investigators: Determinants of 30-day adverse events following saphenous vein graft intervention with and without a distal occlusion embolic protection device</article-title>
          <source>Am J Cardiol</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>173</fpage>
          <lpage>7</lpage>
          <issue>2</issue>
          <volume>95</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Giugliano</surname>
              <given-names>GR</given-names>
            </name>
            <name>
              <surname>Kuntz</surname>
              <given-names>RE</given-names>
            </name>
            <name>
              <surname>Popma</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Cutlip</surname>
              <given-names>DE</given-names>
            </name>
            <name>
              <surname>Baim</surname>
              <given-names>DS</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B23">
        <mixed-citation>23. Mattos LA,    Lemos Neto PA, Rassi A Jr, Marin-Neto JA, Sousa AGMR, Devito FS, et al. Sociedade    Brasileira de Cardiologia. Diretrizes sobre interven&#231;&#227;o coron&#225;ria    percut&#226;nea e m&#233;todos adjuntos diagn&#243;sticos em cardiologia    intervencionista. Arq Bras Cardiol. 2008; 91 (6 supl.1): 1-58.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Sociedade Brasileira de Cardiologia: Diretrizes sobre interven&#231;&#227;o coron&#225;ria percut&#226;nea e m&#233;todos adjuntos diagn&#243;sticos em cardiologia intervencionista</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>2008</year>
          </date>
          <fpage>1</fpage>
          <lpage>58</lpage>
          <issue>6</issue>
          <volume>91</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Mattos</surname>
              <given-names>LA</given-names>
            </name>
            <name>
              <surname>Lemos Neto</surname>
              <given-names>PA</given-names>
            </name>
            <name>
              <surname>Rassi A</surname>
              <given-names>Jr</given-names>
            </name>
            <name>
              <surname>Marin-Neto</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Sousa</surname>
              <given-names>AGMR</given-names>
            </name>
            <name>
              <surname>Devito</surname>
              <given-names>FS</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B24">
        <mixed-citation>24. Smith Jr SC,    Feldman TE, Hirshfeld JW. Percutaneous coronary intervention: ACC/AHA/SCAI 2005    Guideline. J Am Coll Cardiol. 2006; 47 (1): 121.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Percutaneous coronary intervention: ACC/AHA/SCAI 2005 Guideline</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>121</fpage>
          <issue>1</issue>
          <volume>47</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Smith Jr</surname>
              <given-names>SC</given-names>
            </name>
            <name>
              <surname>Feldman</surname>
              <given-names>TE</given-names>
            </name>
            <name>
              <surname>Hirshfeld</surname>
              <given-names>JW</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B25">
        <mixed-citation>25. Simonton CA,    Leon MB, Baim DS, Hinohara T, Kent KM, Bersin RM, et al. Optimal directional    coronary atherectomy: final result of the Optimal Directional Atherectomy Study    (OARS). Circulation.1998; 97 (4): 332-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Optimal directional coronary atherectomy: final result of the Optimal Directional Atherectomy Study (OARS)</article-title>
          <source>Circulation</source>
          <date>
            <year>1998</year>
          </date>
          <fpage>332</fpage>
          <lpage>9</lpage>
          <issue>4</issue>
          <volume>97</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Simonton</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Leon</surname>
              <given-names>MB</given-names>
            </name>
            <name>
              <surname>Baim</surname>
              <given-names>DS</given-names>
            </name>
            <name>
              <surname>Hinohara</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Kent</surname>
              <given-names>KM</given-names>
            </name>
            <name>
              <surname>Bersin</surname>
              <given-names>RM</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B26">
        <mixed-citation>26. Hosokawa H,    Suzuki T,Ueno K, Aizawa T, Fujita T, Takase S, et al. Clinical and angiographic    follow-up of Adjunctive Balloon Angioplasty following Coronary Atherectomy Study    (ABACAS). Circulation. 1996; 94: I-318.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Clinical and angiographic follow-up of Adjunctive Balloon Angioplasty following Coronary Atherectomy Study (ABACAS)</article-title>
          <source>Circulation</source>
          <date>
            <year>1996</year>
          </date>
          <fpage>I</fpage>
          <lpage>318</lpage>
          <volume>94</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Hosokawa</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Suzuki</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Ueno</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Aizawa</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Fujita</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Takase</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B27">
        <mixed-citation>27. The GUIDE Trial    Investigator. IVUS-determined predictors of restenosis in PTCA and DCA: final    report from the GUIDE trial, phase II.(abstract) J Am Coll Cardiol. 1996; 29:    156A.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>IVUS-determined predictors of restenosis in PTCA and DCA: final report from the GUIDE trial, phase II.(abstract)</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>1996</year>
          </date>
          <fpage>156A</fpage>
          <volume>29</volume>
        </element-citation>
      </ref>
      <ref id="B28">
        <mixed-citation>28. Quadros AS,    Ribeiro JP, Manfroi WC, Leit&#227;o C, Ordov&#225;s K, Weiss L, et al. N&#237;veis    plasm&#225;ticos de marcadores imunoinflamat&#243;rios na aterosclerose    coronariana prim&#225;ria e na reestenose coronariana p&#243;s-angioplastia.    Arq Bras Cardiol. 2001; 76 (5): 379-89.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>N&#237;veis plasm&#225;ticos de marcadores imunoinflamat&#243;rios na aterosclerose coronariana prim&#225;ria e na reestenose coronariana p&#243;s-angioplastia</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>2001</year>
          </date>
          <fpage>379</fpage>
          <lpage>89</lpage>
          <issue>5</issue>
          <volume>76</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Quadros</surname>
              <given-names>AS</given-names>
            </name>
            <name>
              <surname>Ribeiro</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Manfroi</surname>
              <given-names>WC</given-names>
            </name>
            <name>
              <surname>Leit&#227;o</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Ordov&#225;s</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Weiss</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B29">
        <mixed-citation>29. Libby P, Schwartz    D, Brogi E, Tanaka H, Clinton SK. A cascade model for restenosis: a special    case of atherosclerosis progression. Circulation. 1992; 86 (6 Suppl): 47-52.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>A cascade model for restenosis: a special case of atherosclerosis progression</article-title>
          <source>Circulation</source>
          <date>
            <year>1992</year>
          </date>
          <fpage>47</fpage>
          <lpage>52</lpage>
          <issue>6</issue>
          <volume>86</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Libby</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Schwartz</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Brogi</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Tanaka</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Clinton</surname>
              <given-names>SK</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B30">
        <mixed-citation>30. Greenberg D,    Bakhai A, Cohen DJ. Can we afford to eliminate restenosis? Can we afford not    to? J Am Coll Cardiol. 2004; 43: 513-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Can we afford to eliminate restenosis?: Can we afford not to?</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>513</fpage>
          <lpage>8</lpage>
          <volume>43</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Greenberg</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Bakhai</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Cohen</surname>
              <given-names>DJ</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B31">
        <mixed-citation>31. Kastrati A,    Sch&#246;mig A, Elezi S, Sch&#252;hlen H, Dirschinger J, Hadamitzky M, et al.    Predictive factors of restenosis after coronary stent placement. J Am Coll Cardiol.    1997; 30 (6): 1428-36.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Predictive factors of restenosis after coronary stent placement</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>1997</year>
          </date>
          <fpage>1428</fpage>
          <lpage>36</lpage>
          <issue>6</issue>
          <volume>30</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Kastrati</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Sch&#246;mig</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Elezi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Sch&#252;hlen</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Dirschinger</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Hadamitzky</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B32">
        <mixed-citation>32. Bauters C,    Hubert E, Prat A. Predictors of restenosis after coronary stent implantation.    J Am Coll Cardiol. 1998; 31 (6): 1291-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Predictors of restenosis after coronary stent implantation</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>1998</year>
          </date>
          <fpage>1291</fpage>
          <lpage>8</lpage>
          <issue>6</issue>
          <volume>31</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Bauters</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Hubert</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Prat</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B33">
        <mixed-citation>33. Elezi S, Kastrati    A, Neumann FJ, Hadamitzky M, Donchinger J, Sch&#246;mig A. Vessel size and long-term    outcome after coronary stent placement. Circulation. 1998; 98 (18): 1875-80.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Vessel size and long-term outcome after coronary stent placement</article-title>
          <source>Circulation</source>
          <date>
            <year>1998</year>
          </date>
          <fpage>1875</fpage>
          <lpage>80</lpage>
          <issue>18</issue>
          <volume>98</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Elezi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kastrati</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Neumann</surname>
              <given-names>FJ</given-names>
            </name>
            <name>
              <surname>Hadamitzky</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Donchinger</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Sch&#246;mig</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B34">
        <mixed-citation>34. Moses JW, Leon    MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, et al.; (SIRIUS Investigators).    Sirolimus-eluting stents versus standard stents in patients with stenosis in    a native coronary artery. N Engl J Med. 2003; 349 (14): 1315-23.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>; (SIRIUS Investigators): Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery</article-title>
          <source>N Engl J Med</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>1315</fpage>
          <lpage>23</lpage>
          <issue>14</issue>
          <volume>349</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Moses</surname>
              <given-names>JW</given-names>
            </name>
            <name>
              <surname>Leon</surname>
              <given-names>MB</given-names>
            </name>
            <name>
              <surname>Popma</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Fitzgerald</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Holmes</surname>
              <given-names>DR</given-names>
            </name>
            <name>
              <surname>O'Shaughnessy</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B35">
        <mixed-citation>35. Stone GW, Ellis    SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, et al; (TAXUS-IV Investigators).    A polymerbased, paclitaxel-eluting stent in patients with coronary artery disease.    N Engl J Med. 2004; 350 (3): 221-31.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>A polymerbased, paclitaxel-eluting stent in patients with coronary artery disease</article-title>
          <source>N Engl J Med</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>221</fpage>
          <lpage>31</lpage>
          <issue>3</issue>
          <volume>350</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Stone</surname>
              <given-names>GW</given-names>
            </name>
            <name>
              <surname>Ellis</surname>
              <given-names>SG</given-names>
            </name>
            <name>
              <surname>Cox</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Hermiller</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>O'Shaughnessy</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Mann</surname>
              <given-names>JT</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B36">
        <mixed-citation>36. Elezi S, Dibra    A, Mehilli J, Pache J, Wessely R, Schomig A, et al. Vessel size and outcome    after coronary drug-eluting stent placement: results from a large cohort of    patients treated with sirolimus- or paclitaxel-eluting stents. J Am Coll Cardiol.    2006; 48 (7): 1304-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Vessel size and outcome after coronary drug-eluting stent placement: results from a large cohort of patients treated with sirolimus- or paclitaxel-eluting stents</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>1304</fpage>
          <lpage>9</lpage>
          <issue>7</issue>
          <volume>48</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Elezi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Dibra</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Mehilli</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Pache</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Wessely</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Schomig</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B37">
        <mixed-citation>37. Kastrati A,    Dibra A, Mehilli J, Mayer S, Pinieck S, Pache J, et al. Predictive factors of    restenosis after coronary implantation of sirolimus- or paclitaxel-eluting stents.    Circulation. 2006; 113 (19): 2293-300.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Predictive factors of restenosis after coronary implantation of sirolimus- or paclitaxel-eluting stents</article-title>
          <source>Circulation</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>2293</fpage>
          <lpage>300</lpage>
          <issue>19</issue>
          <volume>113</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Kastrati</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Dibra</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Mehilli</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Mayer</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Pinieck</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Pache</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B38">
        <mixed-citation>38. Rathore S,    Terashima M, Katoh O, Matsuo H, Tanaka N, Kinoshita Y, et al. Predictors of    angiographic restenosis after drug eluting stents in the coronary arteries:    contemporary practice in real world patients. EuroIntervention. 2009; 5 (3):    349-54.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Predictors of angiographic restenosis after drug eluting stents in the coronary arteries: contemporary practice in real world patients</article-title>
          <source>EuroIntervention</source>
          <date>
            <year>2009</year>
          </date>
          <fpage>349</fpage>
          <lpage>54</lpage>
          <issue>3</issue>
          <volume>5</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Rathore</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Terashima</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Katoh</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Matsuo</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Tanaka</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Kinoshita</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <sub-article article-type="translation" id="TRen" xml:lang="en">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Original Articles</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title xml:lang="en">Angiographic evaluation of plaque volume and cardiovascular events after coronary Stent Implantation</article-title>
      </title-group>
      <abstract xml:lang="en">
        <p>BACKGROUND: Plaque volume (PV) is related to major cardiovascular events (MACE) after coronary stent implantation. OBJECTIVE: To evaluate the association between PV before the procedure evaluated by angiography and clinical outcomes. METHODS: This is a prospective cohort study of patients undergoing coronary stent implantation in a referral center. PV before the stent implantation was evaluated by the formula described by Giugliano (Am J Cardiol 2005, 95:173): VP = &#192; X (lesion length) X [(vessel diameter/2)&#178; - (minimum luminal diameter/2)&#178;]. The MACE were registered at clinical follow-up of one year and multiple linear regression analysis was performed to identify predictors of events. RESULTS: The sample consisted of 824 patients, mean age 60 &#177; 11 years, 70.0% were male. Diabetes mellitus was present in 21.0% and triple vessel involvement in 12.0%. Average reference diameter was 3.3 &#177; 3.2 mm, average lesion length was 10.2 &#177; 4.7 mm and mean residual stenosis was 1.0% &#177; 12.0%. Patients with MACE had higher PV than those without events (92.84 &#177; 42.85 vs 85 &#177; 46.85, p = 0.03). Other variables associated with MACE in the univariate analysis were triple vessel involvement, myocardial infarction, vessel diameter and length of the lesion treated. PV maintained a significant association with MACE after adjusting for the variables described and diabetes mellitus. CONCLUSION: The volume of atheromatous plaque before stenting was higher in patients with MACE on clinical follow-up in one year, regardless of other predictors of events.</p>
      </abstract>
      <kwd-group xml:lang="en">
        <kwd>Angioplasty, transluminal, percutaneous coronary</kwd>
        <kwd>coronary artery disease</kwd>
        <kwd>stents</kwd>
        <kwd>coronary angiography</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>
        <bold>ORIGINAL ARTICLE</bold>
      </p>
      <p>
        <fn id="top-body2">
          <label>
            <bold>Angiographic evaluation of plaque volume and cardiovascular events after coronary stent implantation</bold>
          </label>
          <p>
            <bold>Erlon Oliveira de Abreu-Silva; Alexandre Schaan de Quadros; Marco Tulio Zanettini; Carlos Antonio Gottschall</bold>
          </p>
        </fn>
      </p>
      <p>Instituto de Cardiologia do Rio Grande do Sul/Funda&#231;&#227;o Universit&#225;ria de Cardiologia, Porto Alegre, RS - Brazil</p>
      <p>Mailing address</p>
      <p>
        <bold>ABSTRACT</bold>
      </p>
      <p><bold>BACKGROUND: </bold> Plaque volume (PV) is related to major cardiovascular events (MACE) after coronary stent implantation.</p>
      <p><bold>OBJECTIVE: </bold> To evaluate the association between PV before the procedure evaluated by angiography and clinical outcomes.</p>
      <p><bold>METHODS: </bold> This is a prospective cohort study of patients undergoing coronary stent implantation in a referral center. PV before the stent implantation was evaluated by the formula described by Giugliano (Am J Cardiol 2005, 95:173): VP = &#192; X (lesion length) X [(vessel diameter/2)<sup>2</sup> - (minimum luminal diameter/2)<sup>2</sup>]. The MACE were registered at clinical follow-up of one year and multiple linear regression analysis was performed to identify predictors of events.</p>
      <p><bold>RESULTS: </bold> The sample consisted of 824 patients, mean age 60 &#177; 11 years, 70.0% were male. Diabetes mellitus was present in 21.0% and triple vessel involvement in 12.0%. Average reference diameter was 3.3 &#177; 3.2 mm, average lesion length was 10.2 &#177; 4.7 mm and mean residual stenosis was 1.0% &#177; 12.0%. Patients with MACE had higher PV than those without events (92.84 &#177; 42.85 <italic>vs</italic> 85 &#177; 46.85, p = 0.03). Other variables associated with MACE in the univariate analysis were triple vessel involvement, myocardial infarction, vessel diameter and length of the lesion treated. PV maintained a significant association with MACE after adjusting for the variables described and diabetes mellitus.</p>
      <p><bold>CONCLUSION: </bold> The volume of atheromatous plaque before stenting was higher in patients with MACE on clinical follow-up in one year, regardless of other predictors of events. </p>
      <p><bold>Key words:</bold> Angioplasty, transluminal, percutaneous coronary/prognosis; coronary artery disease; stents; coronary angiography.</p>
      <p>
        <bold>Introduction</bold>
      </p>
      <p>Percutaneous coronary interventions (PCI) are the primary method of myocardial revascularization in current clinical practice<sup>1</sup>. Aiming to estimate the risk and clinical outcome of these patients, various models of risk prediction and therapeutic success have been tested<sup>2-6</sup>. However, the prognostic evaluation of such patients is limited due to the low predictive accuracy of models and risk scores currently available<sup>3-6</sup>. This suggests the need to identify new clinical and angiographic characteristics associated with major cardiovascular events (MACE) in long-term clinical follow-up in patients undergoing PCI.</p>
      <p>Studies evaluating the quantity, area, consistency and volume of coronary atherosclerotic plaque, both by angiography and by intravascular ultrasound (IVUS), have been performed<sup>7-13</sup> and reveal that the amount of plaque, both pre and post-PCI may play a prognostic value in disease progression and outcomes<sup>14-18</sup>. Although the evaluation of atherosclerotic plaque by IVUS is one of the most sensitive methods for evaluation, this technology is costly, and is not available in several centers and cannot be used in subtotal lesions without predilatation with balloon<sup>19-21</sup>.</p>
      <p>The assessment of plaque volume by an estimate based on angiography has been recently described<sup>22</sup>. However, the influence of atherosclerotic plaque volume assessed by angiography on clinical outcomes in patients undergoing coronary stent implantation has not been studied and is purpose of this study.</p>
      <p>
        <bold>Methods</bold>
      </p>
      <p>
        <bold>Patients</bold>
      </p>
      <p>A prospective cohort study in which patients undergoing PCI with coronary stents, from Apr/1997 to Dec/2001 in our institution were considered for inclusion. We excluded patients with cardiogenic shock, implantation of intra-aortic balloon or those with residual stenosis &gt; 30.0% after stent implantation. Clinical, angiographic characteristics, data on procedures and in-hospital complications were prospectively recorded in the Access database.</p>
      <p>The study was approved by the Institutional Ethics Board and participants signed a consent form.</p>
      <p>
        <bold>Clinical characteristics</bold>
      </p>
      <p>Hypertension was considered present when the patient reported history or was taking antihypertensive drugs. Diabetes mellitus and dyslipidemia were defined as previous history or use of oral hypoglycemic agents or insulin, or statins, respectively. Family history was defined by the occurrence of AMI or sudden death by the father (&lt; 45 years) or by the mother (&lt; 55 years). Stable angina was defined as a stable pattern of onset of pain in the last two months before the procedure. Unstable angina was defined as worsening of the intensity and/or frequency of the pattern of angina in the last two months before the procedure, with or without chest pain at rest. Acute myocardial infarction (AMI) as an indication for stent implantation was defined as chest pain and ST-segment elevation requiring immediate revascularization of the infarct-related artery.</p>
      <p>
        <bold>Procedure for coronary stenting</bold>
      </p>
      <p>The patients were receiving aspirin and thienopyridine upon the PCI. Intravenous bolus of unfractionated heparin were administered to achieve an ACT &gt; 300 seconds, and intracoronary nitroglycerin was administered prior to angiography. The procedures for stent implantation were performed as described in literature<sup>23</sup>; and conventional stents were implanted in all cases.</p>
      <p>The clinical success of the procedure was defined as coronary flow TIMI 3 and residual stenosis &lt; 30.0% after stent implantation, without occurrence of death, myocardial infarction or emergency coronary artery bypass grafting. Acute myocardial infarction was defined as elevation of creatine kinase MB fraction (CK-MB)&gt; 3 times the upper limit of normality or development of new pathological Q waves on electrocardiogram.</p>
      <p>
        <bold>Angiographic analysis</bold>
      </p>
      <p>All analyzes were performed with angiographic quantitative coronary angiography (Siemens Axiom Artis, Munich, Germany). The diameter of the target vessel was defined as the average diameter of the segments proximal and distal to the lesion. The severity of stenosis was measured in two orthogonal projections. Longer lesions were considered as a single lesion only when a segment &lt; 10 mm in length was between them. The stenoses were classified according to criteria established by the American College of Cardiology (ACC)<sup>24</sup>; and complex lesions were defined as those of type B2/C.</p>
      <p>Artherosclerotic plaque volume was calculated by the formula proposed by Giugliano et al<sup>22</sup>: VP = &#960; X (lesion length) X [(DRV/2)<sup>2</sup> - (MLD/2)<sup>2</sup>]. We considered &#960; = 3.14, DRV = reference vessel diameter in mm, MLD = minimal luminal diameter in mm.</p>
      <p>
        <bold>Follow-up and clinical outcomes</bold>
      </p>
      <p>Patients were followed for one year by clinical evaluation in the office, contact with the responsible physician or phone interview. Angiographic control was performed for suspected recurrent myocardial ischemia.</p>
      <p>The primary outcome of this study was a combination of MACE including death related to cardiac causes, myocardial infarction (AMI), coronary artery bypass grafting (CABG) and percutaneous revascularization of the target vessel (TVR) within one year after the initial procedure of stent implantation.</p>
      <p>
        <bold>Statistical analysis</bold>
      </p>
      <p>Categorical variables were expressed as percentages and continuous variables as the mean &#177; standard deviation (SD). The differences between the two groups were evaluated by chi-square (categorical variables) and t test (continuous variables). Survival free of MACE during follow-up period of one year was analyzed and the difference between survival curves was evaluated by log-rank test.</p>
      <p>Multivariate analysis by multiple linear regression was performed to identify predictors of MACE in one year. The variables included in the model were associated with MACE in the univariate analysis (plaque volume, lesion length, reference diameter, AMI, and triple vessel involvement) or with biological significance demonstrated in previous studies (diabetes mellitus, lesion length, reference diameter, AMI, and triple vessel involvement).</p>
      <p>For all tests associations with p &lt; 0.05 were considered statistically significant.</p>
      <p>
        <bold>Results</bold>
      </p>
      <p>In this study, 824 patients who underwent implantation of 891 stents met the inclusion criteria and were followed for one year post-PCI.</p>
      <p>The clinical characteristics are presented in <xref ref-type="table" rid="t1-body2">Table 1</xref>, observing that the individuals were predominantly middle-aged men who presented unstable angina. The clinical presentation of MI was more frequent in patients who had MACE, with no statistical significance in comparison with the other variables analyzed.</p>
      <table-wrap id="t1-body2">
        <graphic xlink:href="1678-4170-abc-95-06-0679-00150-gt01-en.jpg"/></table-wrap>
      <p>The angiographic evaluation showed that the average diameter of the vessel studied was 3.3 &#177; 0.32 mm, the mean length of the lesion that suffered intervention was 10.2 &#177; 4.7 mm, and the percentage of residual stenosis after stent implantation was 1 &#177; 12.0% (<xref ref-type="table" rid="t2-body2">Table 2</xref>). Those patients who had MACE had more often three-vessel involvement, thinner vessels and longer lesions.</p>
      <table-wrap id="t2-body2">
        <graphic xlink:href="1678-4170-abc-95-06-0679-00150-gt02-en.jpg"/></table-wrap>
      <p>The artherosclerotic plaque volume before the procedure was significantly higher in individuals who, one year after PCI, showed an outcome consisting of MACE compared to those without events (93 &#177; 43 x 85 mm<sup>3</sup> &#177; 46 mm3, p = 0.03) . This result was irrespective of other variables analyzed in the multivariate analysis model (reference diameter, lesion length, triple vessel involvement, diabetes mellitus and myocardial infarction) (<xref ref-type="table" rid="t3-body2">Table 3</xref> and <xref ref-type="fig" rid="f1-body2">Figure 1</xref>).</p>
      <table-wrap id="t3-body2">
        <graphic xlink:href="1678-4170-abc-95-06-0679-00150-gt03-en.jpg"/></table-wrap>
      <fig id="f1-body2">
        <graphic xlink:href="1678-4170-abc-95-06-0679-00150-gf01-en.jpg"/></fig>
      <p>
        <bold>Discussion</bold>
      </p>
      <p>Our results demonstrate that individuals who had major cardiovascular events (MACE) within one year after stent implantation, plaque volume had before the procedure significantly greater than those individuals who showed no events in the same period. This result was maintained independent of other predictors of events after percutaneous coronary intervention, as demonstrated by multivariate analysis.</p>
      <p>The intracoronary ultrasound is more accurate than angiography for assessment of artherosclerotic plaque volume<sup>13,19</sup>; but it is not available in all centers and adds costs to the procedures. Besides this, in subtotal stenosis it is not possible to introduce the ultrasound catheter without prior balloon dilatation, which prevents the accurate evaluation of more severe stenosis. To test the hypothesis of association between the plaque volume before the procedure and events in the follow-up period, the exclusion of more severe stenoses would represent a significant bias, since these are the cases in which a higher incidence of events would be expected.</p>
      <p>The assessment of atherosclerotic plaque by angiography, as used in this study, was described by Giuliano et al<sup>22</sup> and does not have the limitations described above. The mathematical formula proposed estimates the plaque volume based on the reference diameter, minimal luminal diameter and lesion length. In our study, the plaque volume assessed by angiography presented an independent predictive value for cardiovascular events, and the risk adjusted by multivariate analysis was 1.04 (CI = 1.02 to 1.07).</p>
      <p>Although an excess risk of 4.0% may be considered borderline, it is important to consider that the variable "plaque volume" was expressed in cubic millimeters, ranging from 93 &#177; 43 mm<sup>3</sup> and 85 &#177; 46 mm<sup>3</sup> in each group. Therefore, the 4.0% increase of risk refers to each cubic millimeter of plaque, which is much lower than the standard deviation of each group. If this variable had been used as increments of 10 mm<sup>3</sup>; for example, we would have a 40.0% increase in risk.</p>
      <p>In this trend, Prati et al<sup>18</sup> described the significant direct relationship between the plaque - assessed by angiography - and the same volume assessed by IVUS with the intensity of neointimal proliferation. Similar findings correlating the percentage area of residual plaque and restenosis have been described in the studies OARS<sup>25</sup>; ABACAS<sup>26</sup> and GUIDE II<sup>27</sup>. Berry et al<sup>13</sup> compared angiographic and ultrasound findings of 525 patients, revealing significant correlation in the measurement of plaque volume by both methods. The same study reported that individuals with angiographic evolution of the disease had greater plaque volume measurements by IVUS.</p>
      <p>In our study, we did not explore the mechanisms responsible for the association between artherosclerotic plaque volume before the procedure and the incidence of clinical events. A possible explanation could be related to a higher content of atheroma and inflammatory cells in the arteries with bulkier atheroma. Restenosis and the need for new revascularizations of the target vessel are the main events after PCI, and the association between neointimal proliferation and inflammatory phenomena is well known<sup>28,29</sup>.</p>
      <p>The clinical implications of the association between plaque volume before the procedure and the risk of cardiovascular events in patients undergoing PCIs with stent refer to the stratification of long-term risk in this clinical scenario, as discussed by many previous studies<sup>2-6,27,30-33</sup>. In most studies, the predictors of new events were diabetes mellitus, reference vessel diameter and lesion length treated.</p>
      <p>Our group developed and validated a score system for evaluation of events in which it was possible to identify subgroups of high and low risk for new revascularizations of target-vessel<sup>6</sup>. The angiographic assessment of plaque volume could be a new variable to be included in risk stratification algorithms, considering that the diagnostic accuracy of such models is relatively limited.</p>
      <p>Another important aspect is that the plaque volume would also be predictive of events in patients undergoing implantation of drug-eluting stents, which have been used with increasing frequency in recent years. The capacity of these new devices in reducing intimal hyperplasia that occurs after vascular damage imposed by the stent or balloon, provided a significant reduction in the rates of restenosis and revascularization of target-vessel<sup>34,35</sup>; and the predictors of cardiovascular events in patients treated with drug-eluting stents are similar to those who received conventional stents<sup>36-38</sup>. However, to show an additional predictive value of the plaque volume to known predictors in patients treated with drug-eluting stents would require a much larger number of patients than the present study, since the incidence of events with drug-eluting stents is much smaller.</p>
      <p>In conclusion, we demonstrated that the atherosclerotic plaque volume assessed before stenting by an angiographic method was associated with cardiovascular events in the long term. These results may be used for subsequent evaluations, to investigate whether the plaque volume may increase the diagnostic accuracy of risk stratification algorithms already established, and whether this association also occurs in patients treated with drug-eluting stents.</p>
      <p>Limitations in study design should be considered and include lack of randomization, blinding, and long-term follow-up. Randomized trials comparing this technique for assessment of atherosclerotic plaque with the conventional techniques currently available are becoming essential for the consolidation and validation of this method for diagnosis and prognosis of coronary artery disease.</p>
      <p>
        <bold>Potential Conflict of Interest</bold>
      </p>
      <p>No potential conflict of interest relevant to this article was reported.</p>
      <p>
        <bold>Sources of Funding</bold>
      </p>
      <p>There were no external funding sources for this study.</p>
      <p>
        <bold>Study Association</bold>
      </p>
      <p>This study is not associated with any post-graduation program.</p>
      <p>
        <bold>References</bold>
      </p>
    </body>
  </sub-article>
  <sub-article article-type="translation" id="TRes" xml:lang="es">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Art&#237;culos Originales</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title xml:lang="es">Evaluaci&#243;n angiogr&#225;fica del volumen de placa y eventos cardiovasculares tras implantaci&#243;n de stents coronarios</article-title>
      </title-group>
      <abstract xml:lang="es">
        <p>FUNDAMENTO: El volumen de placa (VP) est&#225; relacionado a eventos cardiovasculares mayores (ECVM) tras implantaci&#243;n de stentscoronarios. OBJETIVOS: Evaluar la asociaci&#243;n entre el VP antes del procedimiento evaluado por angiograf&#237;a y desenlaces cl&#237;nicos. M&#201;TODOS: Se trata de estudio de cohorte prospectivo que incluye a pacientes sometidos a implantaci&#243;n de stentscoronarios en un centro de referencia. El VP antes de la implantaci&#243;n del stent se evalu&#243; por la f&#243;rmula descrita por Giugliano (Am J Cardiol 2005; 95:173): VP = &#928; X (longitud de la lesi&#243;n) X [(di&#225;metro del vaso/2)&#178; - (di&#225;metro luminal m&#237;nimo/2)&#178;]. Los ECVM fueron registrados en el seguimiento cl&#237;nico de un a&#241;o y an&#225;lisis de regresi&#243;n lineal m&#250;ltiple se llev&#243; a cabo para identificar los predictores de eventos. RESULTADOS: La muestra estudiada consisti&#243; en 824 pacientes, con edad promedio de 60 &#177; 11 a&#241;os, con el 70% del g&#233;nero masculino. El diabetes melito estaba presente en el 21,0% y el compromiso triarterial en el 12%. El di&#225;metro medio de referencia fue de 3,3 &#177; 3,2 mm, la media del longitud de la lesi&#243;n fue de 10,2 &#177; 4,7 mm y la media de la estenosis residual fue del 1% &#177; 12%. Los pacientes con ECVM presentaron VP mayor que aquellos sin eventos (92,84 &#177; 42,85 vs 85 &#177; 46,85; p = 0,03). Otras variables asociadas con ECVM en el an&#225;lisis univariado fueron el compromiso triarterial, el IAM, el di&#225;metro del vaso y longitud de la lesi&#243;n tratada. El VP mantuvo la asociaci&#243;n significativa con ECVM tras ajuste para las variables descritas y diabetes melito. CONCLUSI&#211;N: El volumen de la placa del ateroma antes de la implantaci&#243;n del stent fue mayor en los pacientes que presentaron ECVM en el seguimiento cl&#237;nico en un a&#241;o, independientemente de otros predictores de eventos.</p>
      </abstract>
      <kwd-group xml:lang="es">
        <kwd>Angioplastia transluminal percut&#225;nea coronaria</kwd>
        <kwd>enfermedad de la arteria coronaria</kwd>
        <kwd>stents</kwd>
        <kwd>angiograf&#237;a coronaria</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>
        <bold>ART&#205;CULO ORIGINAL</bold>
      </p>
      <p>
        <fn id="top-body3">
          <label>
            <bold>Evaluaci&#243;n angiogr&#225;fica del volumen de placa y eventos cardiovasculares tras implantaci&#243;n de <italic>stents</italic> coronarios</bold>
          </label>
          <p>
            <bold>Erlon Oliveira de Abreu-Silva; Alexandre Schaan de Quadros; Marco Tulio Zanettini; Carlos Antonio Gottschall</bold>
          </p>
        </fn>
      </p>
      <p>Instituto de Cardiologia do Rio Grande do Sul/ Funda&#231;&#227;o Universit&#225;ria de Cardiologia, Porto Alegre, RS -Brasil</p>
      <p>Correspondencia</p>
      <p>
        <bold>RESUMEN</bold>
      </p>
      <p><bold>FUNDAMENTO: </bold> El volumen de placa (VP) est&#225; relacionado a eventos cardiovasculares mayores (ECVM) tras implantaci&#243;n de <italic>stents</italic>coronarios.</p>
      <p> OBJETIVOS: Evaluar la asociaci&#243;n entre el VP antes del procedimiento evaluado por angiograf&#237;a y desenlaces cl&#237;nicos.</p>
      <p> M&#201;TODOS: Se trata de estudio de cohorte prospectivo que incluye a pacientes sometidos a implantaci&#243;n de <italic>stents</italic>coronarios en un centro de referencia. El VP antes de la implantaci&#243;n del stent se evalu&#243; por la f&#243;rmula descrita por Giugliano (Am J Cardiol 2005; 95:173): VP = &#928; X (longitud de la lesi&#243;n) X [(di&#225;metro del vaso/2)<sup>2</sup> - (di&#225;metro luminal m&#237;nimo/2)<sup>2</sup>]. Los ECVM fueron registrados en el seguimiento cl&#237;nico de un a&#241;o y an&#225;lisis de regresi&#243;n lineal m&#250;ltiple se llev&#243; a cabo para identificar los predictores de eventos.</p>
      <p> RESULTADOS: La muestra estudiada consisti&#243; en 824 pacientes, con edad promedio de 60 &#177; 11 a&#241;os, con el 70% del g&#233;nero masculino. El diabetes melito estaba presente en el 21,0% y el compromiso triarterial en el 12%. El di&#225;metro medio de referencia fue de 3,3 &#177; 3,2 mm, la media del longitud de la lesi&#243;n fue de 10,2 &#177; 4,7 mm y la media de la estenosis residual fue del 1% &#177; 12%. Los pacientes con ECVM presentaron VP mayor que aquellos sin eventos (92,84 &#177; 42,85 vs 85 &#177; 46,85; p = 0,03). Otras variables asociadas con ECVM en el an&#225;lisis univariado fueron el compromiso triarterial, el IAM, el di&#225;metro del vaso y longitud de la lesi&#243;n tratada. El VP mantuvo la asociaci&#243;n significativa con ECVM tras ajuste para las variables descritas y diabetes melito.</p>
      <p> CONCLUSI&#211;N: El volumen de la placa del ateroma antes de la implantaci&#243;n del stent fue mayor en los pacientes que presentaron ECVM en el seguimiento cl&#237;nico en un a&#241;o, independientemente de otros predictores de eventos</p>
      <p><bold>Palabras clave:</bold> Angioplastia transluminal percut&#225;nea coronaria / pron&#243;stico, enfermedad de la arteria coronaria, <italic>stents</italic>, angiograf&#237;a coronaria.</p>
      <p>
        <bold>Introducci&#243;n</bold>
      </p>
      <p>Las intervenciones coronarias percut&#225;neas (ICP) son el principal m&#233;todo de revascularizaci&#243;n mioc&#225;rdica en la pr&#225;ctica cl&#237;nica actual<sup>1</sup>. Con el objetivo de estimar el riesgo y la evoluci&#243;n cl&#237;nica de estos pacientes, varios modelos de predicci&#243;n de riesgo y &#233;xito terap&#233;utico se vienen probando<sup>2-6</sup>. Sin embargo, la evaluaci&#243;n pron&#243;stica de dichos pacientes es limitada por la baja exactitud predictiva de los modelos y scores de riesgo disponibles actualmente<sup>3-6</sup>. Dicho hecho sugiere la necesidad de identificaci&#243;n de nuevas caracter&#237;sticas cl&#237;nicas y angiogr&#225;ficas, asociadas a eventos cardiovasculares mayores (ECVM), en el seguimiento cl&#237;nico de largo plazo en pacientes sometidos a ICP.</p>
      <p>Se vienen realizando estudios que eval&#250;an la cantidad, &#225;rea, consistencia y el volumen de la placa ateroscler&#243;tica coronaria, tanto por cineangiocoronariograf&#237;a como por ultrasonido intravascular (IVUS)<sup>7-13</sup> y revelan que el monto de la placa, tanto pre como pos ICP, puede desempe&#241;ar valor pron&#243;stico en la evoluci&#243;n de la enfermedad y en los desenlaces<sup>14-18</sup>. Aunque la evaluaci&#243;n de la placa ateroscler&#243;tica por IVUS es uno de los m&#233;todos con mayor sensibilidad para su evaluaci&#243;n, esta tecnolog&#237;a tiene costo elevado, no est&#225; disponible en diversos centros y no puede utilizarse en lesiones subtotales sin predilataci&#243;n con bal&#243;n<sup>19-21</sup>.</p>
      <p>La evaluaci&#243;n del volumen de la placa por una estimaci&#243;n con base en la angiograf&#237;a se describi&#243; recientemente<sup>22</sup>. Sin embargo, la influencia del volumen de la placa ateroscler&#243;tica evaluada por angiograf&#237;a en la evoluci&#243;n cl&#237;nica de pacientes sometidos a implantaci&#243;n de <italic>stents</italic> coronarios no se estudi&#243; y es objetivo del presente estudio.</p>
      <p>
        <bold>M&#233;todos</bold>
      </p>
      <p>
        <bold>Pacientes</bold>
      </p>
      <p>Estudio de cohorte prospectivo, en el que pacientes sometidos a ICP con <italic>stents</italic> coronarios, entre abr/1997-dic/2001 en nuestra instituci&#243;n, se tuvieron en consideraci&#243;n para la inclusi&#243;n. Se excluyeron a los pacientes con shock cardiog&#233;nico, implantaci&#243;n de bal&#243;n intraa&#243;rtico o a aquellos con estenosis residual &gt; 30,0%, despu&#233;s de la implantaci&#243;n del <italic>stent.</italic> Las caracter&#237;sticas cl&#237;nicas, angiogr&#225;ficas, datos referentes a los procedimientos y complicaciones intrahospitalarios se registraron prospectivamente en banco de datos <italic>Access</italic>.</p>
      <p>El estudio fue aprobado por el consejo de &#201;tica institucional y los participantes firmaron el t&#233;rmino de consentimiento.</p>
      <p>
        <bold>Caracter&#237;sticas cl&#237;nicas</bold>
      </p>
      <p>La hipertensi&#243;n arterial sist&#233;mica se consider&#243; como presente cuando el paciente refer&#237;a historia previa o estaba en uso de f&#225;rmacos antihipertensivos. La diabetes melito y la dislipidemia fueron definidos como historia previa o uso de hipoglucemiantes orales o insulina, o estatina, respectivamente. Historia familiar se defini&#243; por la ocurrencia de IAM o muerte s&#250;bita paterna (&lt; 45 a&#241;os) o materna (&lt; 55 a&#241;os). Angina estable se defini&#243; como la estabilidad del est&#225;ndar de desencadenamiento del dolor en los &#250;ltimos de los meses antes del procedimiento. Angina inestable fue definida como el empeoramiento de la intensidad y/o frecuencia del est&#225;ndar de angina en los &#250;ltimos dos meses antes del procedimiento, con o sin dolor tor&#225;cico en reposo. Infarto agudo de miocardio (IAM) como indicaci&#243;n para la implantaci&#243;n de <italic>stent</italic> se defini&#243; como dolor tor&#225;cico e supradesnivelamiento del segmento ST que necesitaron revascularizaci&#243;n inmediata de la arteria relacionada al infarto.</p>
      <p>
        <bold>Procedimiento de implantaci&#243;n de <italic>stent</italic> coronario</bold>
      </p>
      <p>Los pacientes estaban recibiendo aspirina y tienopirid&#237;nicos por ocasi&#243;n de la ICP. Se administrados <italic>bolus</italic> intravenosos de heparina no fraccionada para alcanzar un TCA &gt; 300 segundos, y nitroglicerina intracoronaria se administr&#243; previamente a la angiograf&#237;a. Los procedimientos de implantaci&#243;n de <italic>stents</italic> se llevaron a cabo conforme descrito en la literatura<sup>23</sup>, siendo que <italic>stents</italic> convencionales se implantaron en todos los casos.</p>
      <p>&#201;xito cl&#237;nico de los procedimientos se defini&#243; como flujo coronario TIMI 3 y estenosis residual &lt; 30,0% tras implantaci&#243;n del <italic>stent</italic>, sin ocurrencia de muerte, infarto agudo de miocardio o cirug&#237;a de revascularizaci&#243;n mioc&#225;rdica de emergencia. Infarto agudo de miocardio se defini&#243; como elevaci&#243;n de la creatinaquinasa fracci&#243;n MB (CK-MB) &gt; 3 veces y l&#237;mite superior de la normalidad o el desarrollo de nuevas ondas Q patol&#243;gicas en el electrocardiograma.</p>
      <p>
        <bold>An&#225;lisis angiogr&#225;fica</bold>
      </p>
      <p>Todos los an&#225;lisis angiogr&#225;ficas se ejecutaron con angiograf&#237;a cuantitativa (<italic>Siemens Axiom Artis,</italic> Munique, Alemania). El di&#225;metro del vaso-blanco de defini&#243; como el di&#225;metro medio de los segmentos proximal y distal a la lesi&#243;n. La severidad de la estenosis se medi&#243; en dos proyecciones ortogonales. Lesiones m&#225;s largas se consideraron como una &#250;nica lesi&#243;n solamente cuando un segmento normal &lt; 10 mm de longitud se encontraba entre ellas. Las estenosis se clasificaron de acuerdo con criterios establecidos por el <italic>American College of Cardiology (ACC)</italic><sup>24</sup>, y lesiones complejas se definieron como aquellas del tipo B2/C.</p>
      <p>El volumen de la placa ateroscler&#243;tica se calcul&#243; por la f&#243;rmula propuesta por Giugliano et al<sup>22</sup>: VP = &#928; X (longitud de la lesi&#243;n) X [(DRV/2)<sup>2</sup> - (DLM/2)<sup>2</sup>]. Se tom&#243; en consideraci&#243;n &#928; = 3,14; DRV = di&#225;metro de referencia del vaso en mm; DLM = di&#225;metro luminal m&#237;nimo en mm.</p>
      <p>
        <bold>Seguimiento y desenlaces cl&#237;nicos</bold>
      </p>
      <p>Los pacientes fueron seguidos durante un a&#241;o por evaluaci&#243;n cl&#237;nica en consultorio, contacto con el m&#233;dico responsable o entrevista por tel&#233;fono. El control angiogr&#225;fico se llev&#243; a cabo en la sospecha de isquemia mioc&#225;rdica recurrente.</p>
      <p>El desenlace primario del estudio fue una combinaci&#243;n de ECAM incluyendo muerte relacionada a causas card&#237;acas, infarto agudo de miocardio (IAM), cirug&#237;a de revascularizaci&#243;n del miocardio (CRM) y revascularizaci&#243;n percut&#225;nea del vaso-blanco (RVA) hasta un a&#241;o tras el procedimiento inicial de implantaci&#243;n del <italic>stent</italic>.</p>
      <p>
        <bold>An&#225;lisis estad&#237;stico</bold>
      </p>
      <p>Las variables categ&#243;ricas se expresaron en percentiles y las variables continuas conforme su media &#177; desviaci&#243;n-est&#225;ndar (DE). Las diferencias entre los dos grupos estudiados se evaluaron por el chi-cuadrado (variables categ&#243;ricas) y por la prueba t (variables continuas). La sobrevida libre de ECAM durante o per&#237;odo de seguimiento un a&#241;o se analiz&#243; y la diferencia entre las curvas de sobrevida se evalu&#243; mediante el m&#233;todo de <italic>log-rank</italic>.</p>
      <p>An&#225;lisis multivariado por regresi&#243;n lineal m&#250;ltiple se llev&#243; a cabo para identificar los predictores de ECAM en un a&#241;o. Las variables incluidas en el modelo se asociaron con ECAM en el an&#225;lisis univariado (volumen de la placa, extensi&#243;n de la lesi&#243;n, di&#225;metro de referencia, IAM y compromiso triarterial) o con significancia biol&#243;gica demostrada en estudios previos (diabetes melito, extensi&#243;n de la lesi&#243;n, di&#225;metro de referencia, IAM y compromiso triarterial).</p>
      <p>Para todas las pruebas realizadas, se consideraron como estad&#237;sticamente significativas las asociaciones con p &lt; 0,05.</p>
      <p>
        <bold>Resultados</bold>
      </p>
      <p>En este estudio, 824 pacientes sometidos a implantaci&#243;n de 891 <italic>stents</italic> completaron los criterios de inclusi&#243;n y tuvieron el seguimiento de un a&#241;o pos ICP.</p>
      <p>Las caracter&#237;sticas cl&#237;nicas est&#225;n detalladas en la <xref ref-type="table" rid="t1-body3">Tabla 1</xref>, observ&#225;ndose que los individuos eran predominantemente varones de media edad y que presentaban cuadro de angina inestable. La presentaci&#243;n cl&#237;nica de IAM fue m&#225;s frecuente en el grupo de pacientes que present&#243; ECAM, sin significancia estad&#237;stica en la comparaci&#243;n entre las otras variables analizadas.</p>
      <table-wrap id="t1-body3">
        <graphic xlink:href="1678-4170-abc-95-06-0679-00150-gt01-es.jpg"/></table-wrap>
      <p>La evaluaci&#243;n angiogr&#225;fica demostr&#243; que el di&#225;metro promedio del vaso estudiado fue de 3,3 &#177; 0,32 mm, la extensi&#243;n media de la lesi&#243;n que sufri&#243; intervenci&#243;n era de 10,2 &#177; 4,7 mm, y el porcentual de la estenosis residual pos <italic>stent</italic> fue de 1 &#177; 12,0% (<xref ref-type="table" rid="t2-body3">Tabla 2</xref>). Los pacientes que presentaron ECAM se hallaron m&#225;s frecuentemente con compromiso triarterial, vasos m&#225;s finos y lesiones m&#225;s largas.</p>
      <table-wrap id="t2-body3">
        <graphic xlink:href="1678-4170-abc-95-06-0679-00150-gt02-es.jpg"/></table-wrap>
      <p>El volumen de la placa ateroscler&#243;tica antes del procedimiento fue significativamente mayor en los individuos que, un a&#241;o despu&#233;s de la intervenci&#243;n percut&#225;nea, presentaron el desenlace compuesto de ECAM en comparaci&#243;n a aquellos sin eventos (93 &#177; 43 mm<sup>3</sup> x 85 &#177; 46 mm<sup>3</sup>; p = 0,03). Dicho resultado se produjo independientemente de las dem&#225;s variables analizadas en el modelo de an&#225;lisis multivariado (di&#225;metro de referencia, extensi&#243;n de la lesi&#243;n, compromiso triarterial, diabetes melito e IAM) (<xref ref-type="table" rid="t3-body3">Tabla 3</xref> y <xref ref-type="fig" rid="f1-body3">Figura 1</xref>).</p>
      <table-wrap id="t3-body3">
        <graphic xlink:href="1678-4170-abc-95-06-0679-00150-gt03-es.jpg"/></table-wrap>
      <fig id="f1-body3">
        <graphic xlink:href="1678-4170-abc-95-06-0679-00150-gf01-es.jpg"/></fig>
      <p>
        <bold>Discusi&#243;n</bold>
      </p>
      <p>Nuestros resultados demuestran que los individuos que presentaron eventos cardiovasculares mayores (MACE), en el per&#237;odo de un a&#241;o tras implantaci&#243;n de <italic>stent,</italic> ten&#237;an volumen de placa antes del procedimiento significativamente mayor que aquellos individuos que no presentaron eventos en el mismo per&#237;odo. Ese resultado se mantuve independientemente de otros predictores de eventos tras la realizaci&#243;n de ICP, conforme demostrado por el an&#225;lisis multivariado realizado.</p>
      <p>El ultrasonido intracoronariano es un m&#233;todo m&#225;s exacto del que la angiograf&#237;a para evaluaci&#243;n del volumen de placa ateroscler&#243;tica<sup>13,19</sup>, pero no est&#225; disponible en todos los centros y agrega costos a los procedimientos. Adem&#225;s de ello, en estenosis subtotales no es posible la introducci&#243;n del cat&#233;ter de ultrasonido sin previa dilataci&#243;n con bal&#243;n, lo que inviabiliza la evaluaci&#243;n exacta de las estenosis m&#225;s severas. Para probar la hip&#243;tesis de la asociaci&#243;n entre el volumen de la placa pre-procedimiento y eventos en el seguimiento, la exclusi&#243;n de las estenosis m&#225;s severas representar&#237;a un sesgo significativo, ya que estos serian los casos en los que una mayor incidencia de eventos se esperar&#237;a.</p>
      <p>La evaluaci&#243;n de la placa ateroscler&#243;tica por angiograf&#237;a utilizada en el presente estudio fue descrita por Giuliano et al<sup>22</sup> y no presenta las limitaciones mencionadas anteriormente. La f&#243;rmula matem&#225;tica propuesta estima el volumen de la placa con base en el di&#225;metro de referencia, di&#225;metro luminal m&#237;nimo y extensi&#243;n de la lesi&#243;n. En nuestro estudio, el volumen de placa evaluado por la angiograf&#237;a present&#243; valor predictivo independiente para eventos cardiovasculares, siendo que el riesgo ajustado por an&#225;lisis multivariado fue de 1,04 (IC = 1,02 - 1,07).</p>
      <p>Aunque un riesgo adicional de un 4% se considera como lim&#237;trofe, es importante tener en cuenta que la variable "volumen de la placa" se expres&#243; en mil&#237;metros c&#250;bicos, variando entre 93 &#177; 43 mm<sup>3</sup> y 85 &#177; 46 mm<sup>3</sup> en cada grupo. Por tanto, el aumento del 4% de riesgo se refiere a cada mil&#237;metro c&#250;bico de placa, que es muy inferior a la desviaci&#243;n est&#225;ndar de cada grupo. Si dicha hubiera sido utilizada conforme incrementos de 10 mm<sup>3</sup>, por ejemplo, hubi&#233;ramos tenido un aumento de un 40% en el riesgo.</p>
      <p>En esta tendencia, Prati et al<sup>18</sup> describieron la relaci&#243;n directa y significativa entre el monto de la placa -evaluado por angiograf&#237;a- y el volumen de la misma evaluada por IVUS con la intensidad de proliferaci&#243;n neointimal. Hallazgos semejantes, correlacionando el porcentual de &#225;rea de la placa residual y reestenosis, se describieron en los estudios OARS<sup>25</sup>, ABACAS<sup>26</sup> y GUIDE II<sup>27</sup>. Berry et al<sup>13</sup>, comparando hallazgos angiogr&#225;ficos y ultrasonogr&#225;ficos de 525 individuos, mostraron correlaci&#243;n significativa en la mensuraci&#243;n del volumen de la placa por los dos m&#233;todos. En el mismo trabajo, se demostr&#243; que los individuos con evoluci&#243;n angiogr&#225;fica de la enfermedad ten&#237;an mayores mediciones volum&#233;tricas de placa por IVUS.</p>
      <p>En nuestro estudio, no se exploraron los mecanismos responsables de la asociaci&#243;n entre el volumen de la placa ateroscler&#243;tica pre procedimiento y la incidencia de eventos cl&#237;nicos. Una posible explicaci&#243;n podr&#237;a estar relacionada a un mayor contenido de ateroma y c&#233;lulas inflamatorias en las arterias con ateromas m&#225;s voluminosos. La reestenosis y la necesidad de nuevas revascularizaciones del vaso blanco son los principales eventos tras las ICP, y la asociaci&#243;n entre la proliferaci&#243;n neointimal y los fen&#243;menos inflamatorios es bien conocida<sup>28,29</sup>.</p>
      <p>Las implicaciones cl&#237;nicas de la asociaci&#243;n entre el volumen de placa pre-procedimiento y el riesgo de eventos cardiovasculares en pacientes sometidos a ICPs con <italic>stents</italic> se refieren a la estratificaci&#243;n de riesgo a largo plazo en esta escena cl&#237;nica, conforme abordado por inn&#250;meros estudios previos<sup>2-6,27,30-33</sup>. En la mayor&#237;a de los estudios, los predictores establecidos de nuevos eventos fueron diabetes melito, di&#225;metro de referencia del vaso tratado y extensi&#243;n de la lesi&#243;n.</p>
      <p>Nuestro grupo desarroll&#243; y valid&#243; un score de puntos para evaluaci&#243;n de eventos, en el que fue posible identificar subgrupos de alto y bajo riesgo para nuevas revascularizaciones del vaso-blanco<sup>6</sup>. La evaluaci&#243;n angiogr&#225;fica del volumen de placa podr&#237;a ser una nueva variable a incluirse en algoritmos de estratificaci&#243;n de riesgo, teniendo en cuenta que la exactitud diagn&#243;stica de dichos modelos es relativamente limitada.</p>
      <p>Otro aspecto importante es si el volumen de placa tambi&#233;n seria predictivo de eventos en pacientes sometidos a implantaci&#243;n de <italic>stents</italic> farmacol&#243;gicos, que han sido usados con frecuencia cada vez mayor en los &#250;ltimos a&#241;os. La capacidad de esos nuevos dispositivos en disminuir la hiperplasia &#237;ntima, que se produce tras el da&#241;o vascular impuesto por el <italic>stent</italic> o bal&#243;n, proporcion&#243; una disminuci&#243;n significativa de las tasas de reestenosis y de revascularizaciones del vaso-blanco<sup>34, 35</sup>, siendo que los predictores de eventos en pacientes tratados con <italic>stents</italic> farmacol&#243;gicos son semejantes a aquellos que recibieron <italic>stents</italic> convencionales<sup>36-38</sup>. Sin embargo, para demostrar un valor predictivo adicional del volumen de placa a los predictores ya conocidos en pacientes tratados con <italic>stents</italic> farmacol&#243;gicos, se har&#237;a necesario un n&#250;mero de pacientes mucho m&#225;s grande que aquello del presente estudio, ya que la incidencia de eventos con los <italic>stents</italic> farmacol&#243;gicos es muy menor.</p>
      <p>En conclusi&#243;n, demostramos que el volumen de la placa ateroscler&#243;tica evaluado antes de implantaci&#243;n de <italic>stent</italic> por un m&#233;todo angiogr&#225;fico se asoci&#243; con eventos cardiovasculares a largo plazo. Dichos resultados se podr&#225;n utilizar para evaluaciones subsiguientes, objetivando investigar si el volumen de placa puede aumentar la exactitud diagn&#243;stica de algoritmos de estratificaci&#243;n de riesgo ya establecidos, y se esta asociaci&#243;n tambi&#233;n se produce en pacientes tratados con <italic>stents</italic> farmacol&#243;gicos.</p>
      <p>Limitaciones inherentes al delineamiento del estudio se deben tener en cuenta e incluyen falta de randomizaci&#243;n, cegamiento y seguimiento a largo plazo. Ensayos cl&#237;nicos randomizados comparando esta t&#233;cnica de evaluaci&#243;n de la placa ateroscler&#243;tica coronaria a las convencionales actualmente disponibles se convirtieron en esenciales para la consolidaci&#243;n y validaci&#243;n de este m&#233;todo diagn&#243;stico y pron&#243;stico de la enfermedad arterial coronaria.</p>
      <p>
        <bold>Potencial Conflicto de Intereses</bold>
      </p>
      <p>Declaro no haber conflicto de intereses pertinentes.</p>
      <p>
        <bold>Fuentes de Financiaci&#243;n</bold>
      </p>
      <p>El presente estudio no tuve fuentes de financiaci&#243;n externas.</p>
      <p>
        <bold>Vinculaci&#243;n Acad&#233;mica</bold>
      </p>
      <p>No hay vinculaci&#243;n de este estudio a programas de postgrado.</p>
      <p>
        <bold>Referencias</bold>
      </p>
    </body>
  </sub-article>
</article>
